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This dissertation comprises the research I conducted in Dr. Jay Hess’ lab from 2009 to 
2013. The objective was to better understand the role of the MLL-HOXA9 axis in 
normal and malignant hematopoiesis. Specifically, I wanted to explore: How is the 
activity of MLL regulated during hematopoiesis? What are the mechanisms of MLL 
fusion mediated transformation? And how does HOXA9 regulate gene expression and 
mediate leukemogenesis? 
The first two questions were tackled by studying the function of the PHD/Bromo 
region of MLL, which is invariably disrupted or deleted in oncogenic MLL fusion 
proteins and is incompatible to MLL fusion-mediated transformation. My studies 
revealed that this region facilitates MLL ubiquitination in multiple ways.  
Chapter 2 describes the role of MLL bromodomain in recruitment of the ECS
ASB2
 E3 
ligase complex. This work was published in Blood, 2012 (Wang, J., Muntean, A.G., 
and Hess, J.L. ECS
ASB2
 mediates MLL degradation during hematopoietic 
differentiation). Chapter 3 describes the intrinsic E3 ligase activity of the second PHD 
finger. This work was published in The Journal of Biological Chemistry, 2012 (Wang, 
J., Muntean, A.G., Wu, L., and Hess, J.L. A subset of mixed lineage leukemia 




The third question was tackled in Chapter 4 by studying the cooperativity between 
Hoxa9 and its potential cofactors C/ebpα and Pu.1. This on-going project is highly 
collaborative: Joel Bronstein focused on protein biochemistry assays; Cailin Collins 
performed all the molecular and cellular assays and prepared libraries for 
ChIP-sequencing and RNA-sequencing; and I performed analysis of the high 
throughput sequencing data, which is presented in this dissertation. Chapter 4 also 
serves as the writing component to partially fulfill the requirements for a dual 
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1.1  MLL in normal and malignant hematopoiesis 
1.1.1 Protein structure and molecular function of wild-type MLL 
The histone H3 lysine4 (H3K4) methyltransferase mixed lineage leukemia protein 
MLL (MLL1) is the human homolog of the Drosophila trithorax protein (Trx). MLL 
is a large protein (3,969 amino acids) with multiple domains. Full length MLL is 
proteolytically cleaved by the protease Taspase1 into a 320 kDa MLL
N
 fragment and 






 non-covalently associate and function 
as a holocomplex (Hsieh et al., 2003a; Hsieh et al., 2003b). On MLL
N
, there are three 
AT hooks with DNA binding capability (Birke et al., 2002), a DNA methyltransferase 
homology region (or CxxC domain) which binds to CpG DNA and also recruits the 
PAF complex through its flanking regions (Cierpicki et al., 2010; Hess, 2004b; 
Muntean et al., 2010), a poorly understood PHD/Bromo region that contains four 
PHD fingers (PHD1-4) and a bromodomain between the third and fourth PHD finger, 





(Hsieh et al., 2003b). On MLL
C
, there is a 




enhancer of zeste, trithorax) domain which has intrinsic H3K4 methyltransferase 
activity (Milne et al., 2002; Nakamura et al., 2002) (Figure 1.1).  
Figure 1.1 Schematic diagram showing the domain structure of wild-type MLL, 
oncogenic MLL fusion proteins and MLL PTD 
 
Figure 1.1. Schematic diagram showing the domain structure of wild-type MLL, oncogenic 
MLL fusion proteins and MLL PTD. (Top) Domain structure of wild-type MLL. Full length 
MLL is proteolytically cleaved by the protease Taspase1 into a 320 kDa MLL
N
 fragment and 
a 180 kDa MLL
C
 fragment. On MLL
N
, there are three AT hooks, a DNA methyltransferase 
homology region (or CxxC domain), a PHD/Bromo region that contains four PHD fingers 
(PHD1-4) and a bromodomain between the third and fourth PHD finger, and a FYRN motif. 
On MLL
C
, there is a transactivation domain, a FYRC motif, and a SET (Su(var)3–9, enhancer 
of zeste, trithorax) domain. (Middle) Chromosomal translocations involving MLL result in 
chimeric MLL-fusion proteins that include the N-terminal sequence of MLL up to the BCR 
(dotted vertical line), followed by one of several different fusion partners. Shown are examples 
of fusion partner proteins, including AF4, ENL, AF9, and AF6. MLL-fusion proteins 
invariably retain AT-hooks and the CxxC domain, while losing the downstream PHD fingers 
and beyond. (Bottom) MLL partial tandem duplications (MLL-PTD) leads to duplication of 
MLL sequences comprising the AT-hooks and the CxxC domain that are inserted at the BCR. 




MLL forms a complex with ASH2, WDR5, hDPY30 and RBBP5 and mediates 
methylation on histone H3 lysine4. This “core complex” is required for the maximal 
enzymatic activity of MLL as knockdown of these components leads to impaired 
MLL methyltransferase activity and deregulation of MLL target genes (Nakamura et 
al., 2002; Wysocka et al., 2005). Methylation of H3K4, particularly trimethylation, is 
closely associated with transcriptional activation, so MLL functions as a positive 
regulator of gene expression. MLL is not a global regulator of H3K4 methylation, as 
knockout of MLL in mouse embryonic fibroblast (MEF) cells only leads to moderate 
decrease of total H3K4me3 (Gregory et al., 2007). Further, it was shown that MLL is 
required for H3K4me3 of only ~5% of the promoters carrying this modification (Wang 
et al., 2009b). However, MLL controls H3K4me3 and maintains expression of a subset 
of genes that play important roles in development and hematopoiesis (Wang et al., 
2009b). The best-studied MLL target genes are homeobox (HOX) transcription factors, 
especially HOXA9 and its co-factor MEIS1, which play critical roles in maintaining 
hematopoietic stem cell identity (discussed below) (Argiropoulos and Humphries, 
2007). Other important MLL target genes include the transcription factor EVI-1, 
another regulator of hematopoiesis (Arai et al., 2011), and the receptor tyrosine kinase 
EPHA7, which regulates MAPK/ERK pathway (Nakanishi et al., 2007) .  




Different models have been established to study the function of MLL at different stages 
of hematopoiesis. Mll knockout mice are embryonic lethal, while heterozygous mice 
show retarded growth, decreased hematopoietic cell populations, and deregulated 
expression of Hox genes (Yu et al., 1995). The yolk sac progenitors from the knockout 
mice have defects in differentiating into multiple hematopoietic lineages (Hess et al., 
1997). Similar phenotype was also observed in another Mll mutant mouse model, in 
which exons 12-14 was replaced with PGK-neo (Yagi et al., 1998). However, mice in 
which only the SET domain is deleted from Mll do not show significant embryonic 
lethality, although the Hox genes show reduced expression, indicating that the 
methyltransferase activity does not account for the complete function of MLL 
(Terranova et al., 2006). Further, inducible knockout mouse model was used to study 
the role of MLL in adult hematopoiesis. Excision of Mll in adult mice leads to fatal 
bone marrow cytopenia within three weeks, probably caused loss of self-renewal in 
hematopoietic stem cells and decreased proliferation of multiple hematopoietic 
progenitors (Jude et al., 2007). Together, these data show that Mll is required for both 
embryonic and adult hematopoiesis. 
1.1.3 MLL fusion mediated leukemia 
1.1.3.1 MLL translocations in human leukemia 
The MLL gene is located at chromosome 11q23. Chromosomal translocations 




representing about 10% of leukemia cases overall (Marschalek, 2011). These include 
up to ~80% of infant acute myeloid (AML) and lymphoid (ALL) leukemia, ~5-10% of 
adult acute leukemia and ~25% of therapy related leukemia, especially in patients 
treated with topoisomerase II inhibitors (Aplan, 2006; Hess, 2004a). Leukemia cases 
with MLL translocations are generally associated with poor prognosis. For example, 
the 5-year survival rate of infant with mixed lineage leukemia is less than 40%, while 
the 5-year survival rate for non-mixed lineage leukemia is nearly 90% (Slany, 2009). In 
chromosome translocations the N-terminus of MLL is fused in frame to a fusion partner 
(Figure 1.1). These oncogenic fusion proteins lead to constitutive activation of HOX 
genes, especially HOXA7, HOXA9 and their cofactor MEIS1, which are required for 
uncontrolled cell proliferation and occurrence of leukemia (Ayton and Cleary, 2003; 
Zeisig et al., 2004). So far, more than 60 MLL fusion partners have been discovered, 
with AF4 (AFF1), ENL (MLLT1), and AF9 (MLLT3) being most frequent in acute 
lymphoid leukemia (ALL), accounting for 80-90% of the MLL-translocation cases, and 
AF9 (MLLT3), AF10 (MLLT10), ELL and AF6 (MLLT4) being most frequent in acute 
myeloid leukemia (AML), accounting for 70-80% of the cases (Marschalek, 2011; 
Meyer et al., 2006). Recent studies also discovered that AF4-MLL and NUP98-MLL, 
which contain the N-terminus of the fusion partner and the C terminus of MLL, can 
have oncogenic properties (Bursen et al., 2010; Kaltenbach et al., 2010). However, 
current observations indicate that these two fusion proteins transform through 




2010). Besides chromosomal translocations, partial tandem duplications (PTD) of 
MLL, are found in AML patients with trisomy 11 (Bernard et al., 1995; Caligiuri et al., 
1996), and ~ 10% of AML patients with normal cytogenetics (Caligiuri et al., 1998; Yu 
et al., 1996). In MLL PTD, MLL exons 5-11 or exons 5-12, which contain the AT hooks 
and the CxxC domain, are duplicated and inserted into intron 4 of the full-length MLL 
(Figure 1.1). However, MLL PTD only moderately up-regulates HOXA9 and requires 
additional mutations, such as FLT3-internal tandem duplication (ITD), to transform, 
indicating that it causes leukemia through different mechanisms from MLL fusion 
proteins (Zorko et al., 2012). This overview will focus on MLL fusion proteins with 
N-terminus of MLL and C-terminus of the fusion partner, as they account for the 
majority of MLL associated leukemia cases.  
1.1.3.2 Mechanisms for MLL-fusion mediated leukemogenesis 
Oncogenic MLL fusion proteins mediate transformation through complicated 
mechanisms that require both MLL and the fusion partner, and involve multiple 
interactions with oncogenic cofactors. The N-terminal 43 amino acid fragment of MLL 
mediates interaction with MENIN, which then interacts with the transcription cofactor 
lens epithelium-derived growth factor (LEDGF) to form a tri-molecular complex 
(Caslini et al., 2007; Grembecka et al., 2010; Yokoyama and Cleary, 2008). This 
interaction is critical for the recruitment of MLL fusion proteins to their target gene loci. 




down-regulate HOX gene expression and reverse oncogenic activity of MLL fusion 
proteins, representing an attractive therapeutic approach for MLL fusion mediated 
leukemia (Grembecka et al., 2012; Shi et al., 2012). Also, the flanking regions of MLL 
CxxC domain recruit the PAF complex, which synergize with MLL fusions to activate 
HOX gene expression. Knockdown of PAF components or deletion of the PAF 
interacting region in MLL-AF9 abolishes its transformation ability (Muntean et al., 
2010).  
While the interactions preserved in MLL N terminus represent global mechanisms for 
MLL fusion mediated transformation, the functions brought by the fusion partners are 
more complicated due to the large number of fusion partners and diversity of their 
molecular function. The MLL fusion partners can be roughly divided into two classes. 
The first class is composed of nuclear proteins, mostly transcription factors, such as 
AF9, AF4, ENL and ELL; while the second class is composed mostly cytoplasmic 
proteins with dimerization ability, such as AF1 and GAS7.  
For nuclear translocation partners, the most well studied mechanism is through 
promoting transcription elongation. Multiple groups have found that MLL fusion 
partners, such as AF9, AF4 and ENL, form a complex with multiple transcription 
elongation factors (Table 1), which promote phosphorylation of RNA polymerase II 
C-terminal domain and thus activation of MLL target genes (Lin et al., 2010; Monroe et 




methyltransferase DOT1L, which is required for MLL fusion mediated transformation 
(Chang et al., 2010a; Okada et al., 2005). Similar to MENIN, DOT1L inhibitors block 
proliferation of MLL leukemia cell lines and show therapeutic potential (Daigle et al., 
2011).  
Table 1-1 MLL fusion partner recruited transcription elongation complex 
Complex Name Components Reference 
Super Elongation 
Complex (SEC) 
P-TEFb complex, ELL2, ELL3, 
EAF1, EAF2 
(Lin et al., 2010) 
AF4/ENL/P-TEFb 
Complex (AEP)  




P-TEFb complex, AF9, ENL, AF4, 
LAF4, AF5Q31, ELL, AF10, DOT1L 
(Monroe et al., 
2010) 
 
The oncogenic mechanisms of MLL fusion proteins with cytoplasmic fusion partners 
are less studied. Interestingly, a number of the cytoplasmic fusion partners contain 
self-association domains, such as the coiled-coil domain in GAS7 and AF1, and the 
Ras-interacting domain in AF6, raising the possibility that dimerization of MLL fusion 
proteins contributes to transformation. Indeed, mutation of the coiled-coil domain 
blocks MLL-GAS7 and MLL-AF1 mediated transformation (So et al., 2003). However, 
although artificially made MLL fusion proteins with synthetic dimerizers enhance 
self-renewal of hematopoietic progenitors, the cells are not completely transformed, 
indicating that additional mechanisms are needed (Martin et al., 2003; So et al., 2003). 
Also, common transformation mechanisms may be used by nuclear and cytoplasmic 




that the AEP complex co-localizes with MLL-AF6 on target gene loci, and MLL-AF6 
mediated transformation requires the presence of DOT1L (Deshpande et al., 2013).  
1.1.3.3 Mechanisms for occurrence of MLL break point 
In MLL translocations, the break point occurs in a breakpoint cluster region (BCR) that 
is ~8.3 kb long and most frequently in MLL intron 9 and intron 11(Meyer et al., 2009). 
Understanding this region of chromosome breakage may provide insight for the 
pathogenesis of MLL fusion mediated leukemia, and several mechanisms have been 
proposed to explain the specific location of MLL breakpoint. Some of them focus on 
the susceptibility of the DNA sequence to double strand break. For example, based on 
the observation that the t(4:11) (MLL-AF4) chromosome translocation breakpoints 
contain heptamer-like or nonamer-like sequences similar to the consensus sequences of 
the immunoglobulin and T-cell antigen receptor (TCR) loci, Gu et al. proposed that 
these translocations may be mediated by abnormal activity of VDJ recombinase. 
However, these heptamer-like and nonamer-like sequences have only been reported in 
two cell lines (MV4:11 and RS4:11), and direct evidence are lacking that VDJ 
recombinase can mediate MLL translocation (Gu et al., 1992). Alu elements are 
repetitive elements accounting for ~10% of human genome (Lander et al., 2001). When 
a DNA double strand break is introduced, an Alu element can recombine with another 
Alu element or non-Alu element, which leads to chromosome translocation (Elliott et 




of them result from homologous Alu recombination and two from heterozygous Alu 
recombination (Strout et al., 1998). However, although Alu recombination seems to be 
a major cause for MLL PTD, it is a rear event for MLL chromosomal translocations, as 
so far only two cases of MLL-AF4 translocation and one case of MLL-AF9 
translocation have been reported that are possibly caused by Alu recombination 
(Reichel et al., 2001; Super et al., 1997). The association of MLL translocation to 
therapy related leukemia, especially in patients treated with DNA topoisomerase II 
inhibitors, raises the possibility that MLL translocation is caused by inhibition of DNA 
topoisomerase II activity. DNA topoisomerases bind to DNA and control its 
topological status by introducing double strand breaks and re-ligation of the DNA, thus 
playing critical roles in gene transcription and DNA replication. DNA topoisomerase II 
inhibitors, such as doxorubicin and etoposide, interfere with the activity of DNA 
topoisomerase II by promoting cleavage or preventing re-ligation of the DNA, thus 
leading to increased DNA double strand break and apoptosis of the highly proliferating 
cancer cells. These inhibitors have been widely used in the treatment of cancers such as 
breast cancer, lung cancer and testicular cancer (Nitiss, 2009). Not surprisingly, the 
increased DNA double strand breaks and non-homologous end joining (NHEJ) leads to 
increased possibility of chromosomal translocation. Indeed, in vitro assays have shown 
that etoposide and its metabolites enhance topoisomerase II mediated cleavage near the 
BCR of MLL gene (Ishii et al., 2002; Lovett et al., 2001), and another study shows that 




topoisomerase II cleavage in vitro (Whitmarsh et al., 2003). Of course, in vivo 
experiments are needed to prove this model, and whether it also explains the occurrence 
of de novo MLL translocations remains to be determined.  
Notably, besides accessibility of the DNA sequence to double strand break, another 
prerequisite for chromosome translocations to occur and be detected is that the fusion 
proteins gain oncogenic ability. In other words, the break point occurs so that regions 
that are required for oncogenesis are preserved while regions that are incompatible with 
oncogenesis are deleted. In most if not all MLL translocations, the break point happens 
after the CxxC region and before or within the first PHD finger, thus the CxxC region is 
invariably preserved while the PHD/Bromo region disrupted or deleted from oncogenic 
MLL fusion proteins. Indeed, our lab has shown that, although insertion of the first 
PHD finger into a MLL-AF9 construct does not affect its ability to transform murine 
bone marrow cells, insertion of the first two PHD fingers and beyond abolishes its 
transformation ability (Muntean et al., 2008). Similarly, insertion of the third PHD 
finger into MLL-ENL fusion proteins blocks transformation (Chen et al., 2008). These 
findings indicate that the PHD/Bromo region has important roles in the regulation of 
MLL activity, which is the focus of this dissertation. At the same time, Muntean et al. 
show that sequences flanking the MLL CxxC domain recruit the PAF complex, which 
promotes MLL-AF9 mediated transcriptional activation and is required for the 




1.1.4 PHD finger 
1.1.4.1 Structure of PHD fingers 
Plant Homeo Domain (PHD) fingers are widely distributed zinc-binding motifs that 
have been found in more than 200 human proteins, especially transcription factors and 
chromatin modifier enzymes. Typical PHD fingers are 50-80 amino acids long and 
contain a Cys4-His-Cys3 (C4-H-C3) consensus. The conserved cysteine and histidine 
residues coordinate two Zn
2+
 ions in a cross-brace topology, and maintain the stability 
of the domain structure (Bienz, 2006) (Figure 1.2). Several other classes of 
zinc-binding motifs share structural and functional similarity to PHD fingers, such as 
RING domains with C3-H-C4 consensus, LIM domains with C2-H-C-C/H/D/E 
consensus, MYND domains with C/H-C4-C/H-H-C consensus and FYVE domains 
with C8 consensus (Matthews et al., 2009). Although being structurally conserved, 
the conservation of amino acid sequences among PHD fingers is generally low, which 




Figure 1.2 Structure of PHD finger and RING finger 
 
Figure 1.2 Schematic showing the structure of PHD finger and RING finger. The conserved 
Cysteine and Histidine residues coordinate Zn
2+
 ions in a cross-brace topology, and maintain 
the stability of the domain. Zn: Zn ion. C and H: conserved cysteine and histidine residues. 
Green arrow: β-strand. Purple: α-helix.  
1.1.4.2 Function of PHD fingers 
1.1.4.2.1 Binding to histone marks 
Post-translational modifications of histones, such as methylation, acetylation, 
phosphorylation and ubiquitination, mark the chromosome status and play important 
roles in recruiting transcription factors and chromosome modifiers (Jenuwein and 
Allis, 2001). The best-studied function of PHD fingers is to bind to histone marks, 
mostly on histone H3, and function as “epigenetic readers”. For example, the PHD 
fingers of AIRE and UHRF1 bind to unmodified histone H3 (Chakravarty et al., 2009; 
Chignola et al., 2009; Lallous et al., 2011; Org et al., 2008; Rajakumara et al., 2011; 
Wang et al., 2011a); the PHD fingers of ING proteins (ING1-5), BPTF, YNG1 and 




Martin et al., 2006; Matthews et al., 2007; Pena et al., 2006; Pena et al., 2009; 
Ramon-Maiques et al., 2007; Taverna et al., 2006; Wysocka et al., 2006); the PHD 
finger of CHD4 binds to H3K9me3 (Mansfield et al., 2011); the PHD finger of NTO1 
binds to H3K36me3 (Shi et al., 2007); and the PHD finger of DPF3b and MOZ bind 
to H3K14ace (Qiu et al., 2012; Zeng et al., 2010). Besides individual binding, 
multiple PHD fingers can bind cooperatively to one histone modification. For 
example, the two tandem PHD fingers in DPF3 function as one unit and bind to 
H3K14ac (Zeng et al., 2010).  
In most cases, binding of PHD finger to histone marks recruits protein or protein 
complex to the chromosome, while the biological effect of this recruitment, such as 
chromatin modification, transcription activation or repression, is largely decided by 
other effector domains of the protein or other subunits of the protein complex. One 
example is the inhibitor of growth (ING) family proteins. All the ING family 
members (ING1-5) contain a C terminal PHD finger that show ~80% sequence 
homology and bind to H3K4me3 in highly similar conformations through an aromatic 
cage. This binding recruits the ING containing complexes to the target gene loci. 
ING1 and ING2 associate with Sin3A/HDAC1/2 repressor complex, which lead to 
transcriptional repression. On the contrary, ING3, ING4 and ING5 associate with 




complex, respectively, which lead to transcriptional activation (Champagne and 
Kutateladze, 2009).  
PHD fingers recognize histone modifications and are responsible for the proper 
recruitment of transcription factors and chromatin modifiers, so the specificity of 
PHD finger-histone mark interaction must be accurately controlled. This is achieved 
on multiple levels. First, structures have been solved for a number of PHD fingers 
interacting with different histone peptides, which reveal that the binding specificity 
depends on sequence and conformation of PHD fingers. For example, the H3K4me3 
binding PHD fingers, such as those of BPTF and RAG2, contain an aromatic cage 
formed by two to four aromatic and hydrophobic residues, including an invariable Trp 
residual, which accommodates the methylated H3K4 side chain (Li et al., 2006; 
Ramon-Maiques et al., 2007). Mutation of the Trp residual in the PHD finger of 
BPTF reduces its binding affinity for more than 20 fold. Similar effects are also 
observed when the other three amino acids lining the aromatic cage are mutated (Li et 
al., 2006). However, in H3K4me0 binding PHD fingers, such as those of AIRE and 
DNMT3L, the aromatic cage is replaced by acidic and hydrophobic residues that form 
multiple hydrogen bonds to unmethylated H3K4 (Chakravarty et al., 2009; Chignola 
et al., 2009). The H3K4me0-binding PHD finger of UHRF1 represents an atypical 
PHD finger. Although it does not have the conserved C terminal acidic residual, an 




chain (Lallous et al., 2011). Secondly, adjacent residues on histone H3 may have 
positive or negative effects on the binding affinity of PHD fingers. For example, Arg2 
on H3 affects the binding of PHD fingers, especially those bind to unmethylated or 
methylated H3K4, in different ways. For the PHD finger of AIRE, Arg2 occupies a 
groove adjacent to the groove occupied by H3K4me3 and form direct contact with the 
PHD finger through ionic and hydrogen-bonding interactions. This is required for the 
PHD-H3K4me3 interaction, as methylation of Arg2 abolishes the interaction 
(Chignola et al., 2009). On the contrary, in the PHD finger of RAG2, the carboxylate 
(an Asp or Glu) that interacts with Arg2 was replaced by a Tyr, which forms 
interaction with methylated Arg2, so its binding to H3K4me3 is enhanced rather than 
inhibited by dimethylation of Arg2. Notably, mutation of this Tyr reverses this 
binding preference as the mutant binds to the singly modified (K4me3) over doubly 
modified (K4me3/R2me2) H3 peptide by 3- to 4-fold (Ramon-Maiques et al., 2007). 
Finally, PHD fingers generally exist in proteins in a tandem manner with other PHD 
fingers, or adjacent to other chromosome binding motifs, such as bromodomains, 
chromodomains and tandem tudor domains. These adjacent domains may cooperate 
with PHD finger to define its binding specificity. One example is UHRF1, in which 
the PHD finger binds to unmodified R2 of histone H3 tail, while the adjacent tandem 
tudor domain binds to H3K9me3. Together, they recognize specific H3 tails and are 
critical for the proper recruitment of UHRF1. Similarly, in TIF1r, the PHD finger 




the adjacent bromodomain binds to the C terminus of the same H3 tails with 
acetylated lysines (Agricola et al., 2011).   
1.1.4.2.2 Binding to other proteins 
Besides histone marks, PHD fingers can also bind to other proteins. Examples include 
the PHD finger of Pygo2, which binds to the B9L/BCL9 cofactor, and the third PHD 
finger of MLL, which binds to Cyp33. Interestingly, for both of them, the PHD finger 
binds to histone tail and another protein simultaneously through different surfaces and 
binding of the protein affects the binding affinity to histone tail. The PHD finger of 
Pygo2 binds to the HD1 domain of B9L/BCL9 cofactor on one surface, and 
methylated histone H3 on another surface. Structural studies show that binding of 
HD1 leads to an allosteric conformational change of the PHD finger, especially the 
conserved isoleucine residue (I344) between the two grooves that accommodate 
H3A1 and H3K4me, which promotes its binding to methylated H3K4. Consistent 
with this, the binding affinity is 2~3 fold higher in the presence of HD1 compared to 
that without HD1; and mutation of I344 and W377, the residues that mediate 
interaction with HD1, leads to decreased binding affinity to methylated H3K4 (Fiedler 
et al., 2008; Miller et al., 2010). Similarly, the third PHD finger of MLL binds to 
H3K4me3 and Cyp33 simultaneously through different surfaces. This is achieved by a 
PPIase-mediated cis-to-trans conformational transition of the Pro1629 of MLL, which 




of Cyp33 leads to recruitment of HDAC and switches MLL from a transcription 
activator to a transcription repressor. Unlike Pygo2, binding of Cyp33 leads to ~ 2 
fold decrease in the binding affinity of MLL to histones (Park et al., 2010; Wang et al., 
2010). Other examples of protein binding PHD fingers include the PHD finger of 
Hepatitis B virus X-associated protein (HBXAP) which interact with Hepatitis B virus 
pX, and the PHD finger of Polycomb-Like Protein 1 (PHF1) which binds to EZH2 
(O'Connell et al., 2001; Shamay et al., 2002). Further, all the PHD fingers with E3 
ligase activity (discussed below) interact with E2 conjugating enzymes.  
1.1.4.2.3 Binding to lipids and DNA 
Besides binding to proteins, the PHD finger of ING2 has been shown to bind to 
Phosphoinositides (PtdInsPs), which is required for ING2 mediated p53 acetylation 
and activation of p53 related pathways. This binding ability is probably due to the 
structural similarity of the PHD finger to the FYVE domain, a well-known 
Phosphoinositides binding module, and is mediated by two basic patches in the 
middle and C terminus of the PHD finger. Similar binding ability was also observed 
for PHD fingers of ACF, MLZF and WSTF (Gozani et al., 2003). Notably, the same 
PHD finger of ING2 can also bind to H3K4me3 (Shi et al., 2006). Although the key 
amino acid residues identified for PtdInsPs binding are different from those identified 
for H3K4me3 binding, it remains to be determined if the two interactions occur 




Although PHD fingers have long been believed to lack direct DNA binding ability, 
recently Liu L et al., reported that the second PHD finger of BRPF2 can bind DNA 
non-specifically, while having no affinity for unmethylated or methylated histones 
(Liu et al., 2012). In this PHD finger, the binding to DNA is mediated through a 
positively charged surface; the characteristic aromatic cage responsible for H3K4me3 
binding is replaced by short-side-chain residues like Thr or Ser, and the segment that 
forms hydrogen bonds to the N termimus of H3 is also replaced by a β-sheet. This 
may represent a new subclass of PHD fingers.  
1.1.4.2.4 PHD finger as ubiquitin E3 ligase  
Ubiquitination is a post-translational modification that plays an important role in 
protein degradation and signal transduction. During ubiquitination, one or more 
ubiquitin molecules are attached to lysine residues of a substrate through sequential 
activity of three enzymes, an E1 activating enzyme, an E2 conjugating enzyme and an 
E3 ligase. The substrate is then targeted to proteasome-mediated degradation or other 
signal transduction pathways (Pickart, 2001). E3 ligases directly bind to target proteins, 
thus defining the specificity of the reaction. The structural similarities between PHD 
fingers and RING fingers (Figure 1.2), which are known to function as E3 ligases, 
raise the possibility that PHD fingers may also have similar activity (Capili et al., 
2001). The E3 ligase activity of PHD finger was first discovered in Kaposi’s 




and MIR2, mediate down-regulation of cell surface molecules, such as MHC-I, B7.2 
and ICAM-1, thus impairing the recognition of infected cells by the immune system. 
This down-regulation depends on the lysine residues of the surface molecules, and is 
through ubiquitination and degradation by the endocytosis system. Further, in vitro 
ubiquitination assays showed that the PHD fingers of MIR1 and MIR2 contain E3 
ligase activity in the presence of ATP, E1 activating enzyme and E2 conjugating 
enzyme, while disruption of the PHD finger abolishes the activity and 
down-regulation of cell surface molecules (Coscoy et al., 2001). Later, the PHD 
fingers of several eukaryotic proteins were also discovered to contain E3 ligase activity, 
including the yeast protein Msc1, and the mammalian proteins MEKK1, AIRE. In the 
current study, we found that the second PHD finger of MLL also has intrinsic E3 
ligase activity (Dul and Walworth, 2007; Lu et al., 2002; Uchida et al., 2004; Wang et 
al., 2012). All the proteins with E3 ligase PHD fingers tested so far leads to 
ubiquitination and degradation of the protein itself or other targets. However, these 
proteins are quite diverse in their localization and molecular functions. For example, 
MEKK1 localizes in the cytoplasm and regulate the MAP kinase pathway by 
degrading ERK1/2; while AIRE localizes to the nucleus and functions as transcription 
factor. Besides ubiquitin E3 ligase activity, the PHD finger of KAP1 has been shown 
to have sumo (Small Ubiquitin-like Modifier) E3 ligase activity (Ivanov et al., 2007). 
Sumoylation is a post-translational modification that is very similar to ubiquitination. 




sumo E1 activating enzyme, E2 conjugating enzyme (UBC9) and E3 ligase, which 
then regulates transcriptional regulation, protein stability and signal transduction (Hay, 
2005). KAP1 functions to recruit the nucleosome remodeling and deacetylation 
(NuRD) complex and SETDB1 histone H3K9 methyltransferase to target loci, and 
mediates transcription repression (Schultz et al., 2002; Schultz et al., 2001). It has 
been shown that the PHD finger of KAP1 interacts with UBC9 sumo E2 conjugating 
enzyme, and mediates sumoylation of the adjacent bromodomain in vitro and in vivo. 
Both SETDB1 and CHD3, the subunits of NuRD complex, contain a 
SUMO-interacting motif and interact with KAP1 through sumo binding. So this 
activity is critical for the recruitment of NuRD (Capili et al., 2001; Ivanov et al., 2007; 
Zeng et al., 2008).  
1.1.4.3 PHD fingers in human disease 
As PHD fingers play important roles in recruitment, stability and activity of proteins, 
mutations of these domains are associated with various human diseases. 
One example is RAG2. RAG2 is a core component of the RAG complex, which 
mediates DNA cleavage during V(D)J recombination. The PHD finger of RAG2 has 
been shown to bind to H3K4me3, which recruits the complex to the chromosome and 
is required for efficient DNA recombination (Oettinger et al., 1990). Deletion of 
RAG2 in mouse model fails to initiate V(D)J recombination and have severe defect in 




phenotype (Shinkai et al., 1992). Mutations of RAG2 have been found in patients with 
SCID and Omenn immunodeficiency syndrome with several of them occuring in the 
PHD domain (Gomez et al., 2000). One of the mutations found in Omenn syndrome 
occurs on W453, which is one of the highly conserved aromatic residues on the 
binding surface to H3K4me3. It has been shown that this mutation abrogates 
H3K4me3-binding by RAG2 (Matthews et al., 2007). Similarly, mutations of C478Y 
and H481P, two of the conserved Cysteine and Histidine residues are found in SCID 
patients (Noordzij et al., 2002; Schwarz et al., 1996).  
On the contrary, gain of function of PHD fingers is also associated with human 
diseases. Nucleoporin 98 (NUP98) is a component of the nuclear pore complex which 
mediates mRNA export from the nucleus. Chromosome translocations of NUP98, 
which fuses NUP98 to another fusion partner, are commonly found in hematopoietic 
malignancies, including acute myeloid and lymphoid leukemia and myelodysplastic 
syndrome. So far more than 20 fusion partners of NUP98 have been discovered and 
one class of them is PHD fingers, including the PHD finger of JARID1A or PHF23 
(Moore et al., 2007; Wang et al., 2009a). These PHD fingers have been shown to bind 
to H3K4me3. Indeed, the NUP98-PHD fusion proteins are recruited to the genomic 
loci with high H3K4me3 signals, with a number of them being genes involved in 
hematopoietic stem cell and progenitor self-renewal, such as HOX genes and MEIS1. 




maintains the constitutive activation of these genes, which mediate leukemogenesis. 
The oncogenic activity of NUP98-PHD fusions is dependent on the intact function of 
the PHD fingers, as mutation of the PHD fingers abolishes their transformation ability 
(Wang et al., 2009a). Another fusion partner of NUP98, NSD3, also contains a PHD 
finger, although whether the oncogenic ability of this fusion protein depends on the 
activity of the PHD finger remains to be determined. 
So far, no disease-associated mutations have been discovered that specifically target 
the E3 ligase activity. However, this possibility cannot be excluded as disruption of 
these PHD fingers thus their E3 ligase activity definitely impairs the normal function 
of the proteins (Lu et al., 2002; Uchida et al., 2004). Notably, the first PHD finger of 
AIRE has been shown to have both E3 ligase activity and histone binding ability. 
Missense mutations of this PHD finger (C311Y and P326Q) have been discovered as 
the causal mutations for autoimmune-polyendocrinopathy-candidiasis ectodermal 
dystrophy (APECED). However, it remains to be determined if the disease is caused 
by loss of the E3 ligase activity, or loss of the histone binding activity, or both 
(Uchida et al., 2004). Another example may be MLL, as the PHD/Bromo region, 
including the second PHD finger with E3 ligase activity, is invariably deleted from 





Bromodomain is another class of motifs that commonly bind to histone marks and 
function as epigenetic reader. Bromodomains are generally ~100 amino acid long and 
contain a bundle of four α-helices and inter-helical ZA and BC loops (Mujtaba et al., 
2007). So far, 121 human proteins have been discovered to contain one or more 
bromodomains, with most of these proteins being transcription factors and chromatin 
modifiers. Like PHD fingers, bromodomains recognize and bind to acetylated 
histones, and recruit proteins or protein complexes to the genome. Examples include 
the bromodomain of the histone acetyltransferase GCN5, the transcription 
co-activator PCAF (p300/CREB-binding protein-associated factor) and TAF1, the 
SWI/SNF chromosome remodeling complex component BRG1, and the BET family 
protein BRDs (Dhalluin et al., 1999; Hudson et al., 2000; Jacobson et al., 2000; 
Nakamura et al., 2007; Shen et al., 2007). Structural studies show that bromodomain 
binds to acetylated lysine residual through its hydrophobic groove, which is highly 
conserved among acetyl-binding bromodomains (Owen et al., 2000). Most of the 
bromodomains studied have broad recognition specificity and bind to multiple 
acetylated lysine residues on histone H2B, H3 and H4 in vitro, while in vivo, the 
binding specificity may be achieved by cooperation of adjacent domains (Zeng et al., 
2008).  
Besides acetylated histones, bromodomains also bind to other acetylated proteins. For 




K382 of p53, which is responsible for p53 recruitment of CBP upon DNA damage, 
and p53-induced transcriptional activation (Mujtaba et al., 2004). Also, the 
bromodomain of PCAF binds to acetylated lysine of the human immunodeficiency 
virus type 1 (HIV-1) trans-activator protein Tat in a very similar mode as binding to 
acetylated histones, which stimulates the transcription of the integrated virus genome 
(Mujtaba et al., 2002).  
Although the hydrophobic groove is highly conserved among acetyl-lysine binding 
bromodomains, the overall amino acid sequences, especially the ZA and BC loops can 
be very diverse (Jeanmougin et al., 1997). A sequence analysis of 56 human 
bromodomains was reported, which classifies these bromodomains into 9 classes. 
Notably, the MLL bromodomain was defined as an outlier, due to significant sequence 
variation (Sanchez et al., 2000; Sanchez and Zhou, 2009). Consistent with this, 
although this bromodomain exhibits a typical bromodomain fold, it does not recognize 
acetylated histones, perhaps due to loss of a conserved asparagine found in 
acetyl-lysine binding bromodomains (Wang et al., 2010). In this study, we discovered 
that the bromodomain of MLL has a novel function, which is to recruit the E3 ligase 
ASB2 and mediates ubiquitination and degradation of MLL.   
Adjacent PHD finger and bromodomain are commonly found in proteins and have 
intensive functional interactions. One example is the PHD –bromodomain module in 




unmethylated K4 and R2, while the adjacent bromodomain binds to the C terminus of 
the same H3 tails with acetylated lysines. Together, the two modules define a specific 
binding pattern for the recruitment of TIF1γ (Agricola et al., 2011). Another example 
is KAP1, in which the PHD finger has sumo ligase activity that mediates sumoylation 
of the adjacent bromodomain, which is required for the recruitment and proper 
function of KAP1 (Ivanov et al., 2007).  
Bromodomains are closely associated with pathogenesis of human diseases. One 
example is BRD4, which is a key regulator of cell cycle by interacting with cyclin T1 
and CDK9 of the P-TEFb complex (Jang et al., 2005). The t(15;19)(q15;p13) 
translocation fuses the nuclear protein in testis (NUT) to BRD4, which is believed to 
be the driving mutation of NUT midline carcinoma. Although this is a rare tumor, it is 
highly aggressive and is almost uniformly lethal (French et al., 2003). Studies 
discovered that the bromodomain from BRD4 binds to acetylated histones on the 
chromosome, while the NUT fragment sequester p300, which leads to histone 
hyper-acetylation mediated chromosome compaction and transcriptional inactivation 
of key target genes (Reynoird et al., 2010). Besides being a direct driving mutation for 
tumorigenesis, an RNAi screening identified BRD4 as the top gene that is required for 
MLL fusion mediated leukemogenesis. This is possibly due to its important role in 
cell cycle regulation, thus BRD4 represents an example of non-oncogene addiction. 




mediated leukemogenesis in vitro and in vivo, thus representing an attractive 
therapeutic strategy (Dawson et al., 2011; Zuber et al., 2011). Further, it was shown 
that BRD4 inhibitor can target the MYC pathway, and is effective for a broad range of 
AML leukemia cases not limited to MLL translocation (Zuber et al., 2011).  
1.2  HOXA9 is a key target gene of MLL 
1.2.1 HOXA9 in MLL mediated leukemia 
HOXA9 and its cofactor MEIS1 are the best-studied MLL target genes and are required 
for MLL fusion mediated leukemogenesis (Ayton and Cleary, 2003; Wong et al., 2007). 
HOXA9 is a member of the HOX transcription factor family. It specifies segment 
identity and cell fate during development and plays an essential role during 
hematopoiesis (Argiropoulos and Humphries, 2007). HOXA9 maintains the 
self-renewal ability of hematopoietic stem cells and progenitors. Hoxa9-deficient mice 
show severe impairment of the repopulation ability of HSCs and have defects in 
development of multiple hematopoietic lineages. During hematopoietic differentiation, 
HOXA9 expression decreases, this is required for the normal progression of 
hematopoiesis (Pineault et al., 2002). 
MLL positively regulates the expression of HOXA9 and MEIS1 in hematopoietic stem 
cells and progenitors (Jude et al., 2007; McMahon et al., 2007; Wang et al., 2009b). 
Mll-null mice are defective in maintaining Hox gene expression resulting in embryonic 




rescues hematopoietic colony formation (Ernst et al., 2004; Yu et al., 1995). On the 
other hand, MLL fusion proteins constitutively activate HOXA9 and MEIS1, which 
leads to uncontrolled cell proliferation and is required for MLL fusion mediated 
leukemia. Consistent with this, MLL fusion proteins are unable to transform HOXA9 
or MEIS1 knockout murine bone marrows in vitro or induce leukemia in vivo (Ayton 
and Cleary, 2003; Wong et al., 2007). Further, overexpression of HOXA9 and MEIS1 
could replace the transformation ability of MLL-ENL fusion protein (Zeisig et al., 
2004).  
Besides MLL fusion mediated leukemia, up-regulation of HOXA9 is also associated 
with a variety of human leukemias, such as NPM1 mutation-associated AML and 
CDX2/CDX4 mediated leukemia (Bansal et al., 2006; Mullighan et al., 2007; Rawat 
et al., 2008). In fact, overexpression of HOXA9 is present in approximately 50% of all 
AML cases (Lawrence et al., 1999). HOXA9 was identified as the most highly 
correlated gene for poor prognosis in AML (Golub et al., 1999; Lawrence et al., 1999), 
while low expression of HOXA9 associates with favorable AMLs (Debernardi et al., 
2003). Also, HOXA9-NUP98 fusion resulting from chromosome translocation leads 
to aberrant gene expression profiling and is associated with AML, trilineage MDS and 
chronic myelomonocytic leukemia (Borrow et al., 1996; Hatano et al., 1999; Inaba et 
al., 1996; Kroon et al., 2001; Nakamura et al., 1996; Wong et al., 1999).  




Although it has been established for a long time as the key regulator of hematopoiesis 
and important mediator of leukemia, how HOXA9 regulates gene expression remains 
poorly understood. For example, all the HOX proteins bind to similar AT rich 
sequences through their highly homologous homeodomain, so how does HOXA9 
specifically recognize its target genes (Laughon, 1991)? Also, as HOXA9 can both 
activate and repress gene expression, how is the specific activity determined (Huang 
et al., 2012)? To solve these questions, the concept of “Hoxasome” was brought up, 
meaning that transcription factors and chromatin modifiers (HOXA9 cofactors) form 
a complex with HOXA9 and bind to DNA in a cooperative pattern, thus increasing 
the binding specificity, affinity or transactivation ability of HOXA9 (Mann et al., 
2009). One example of HOXA9 cofactor is the non-Hox homeodomain protein 
MEIS1. MEIS1 can dimerize with HOXA9, or form a triple complex with HOXA9 
and PBX proteins (PBX1-3), another class of HOXA9 cofactors that contain a 
homeodomain with ~40% identity to that of MEIS1. These interactions stabilize the 
HOXA9 DNA binding complex. In in vitro binding assays, addition of MEIS1 leads 
to a 10-fold increase of PBX2-HOXA9 interaction; while addition of PBX2 leads to a 
5-fold increase of MEIS1-HOXA9 interaction. Further, addition of MEIS1 binding 
consensus (TGACAG) and PBX binding consensus (TGAT) increases the specificity 
of HOXA9 recognition on target loci (Shen et al., 1997; Shen et al., 1999).  
To better understand the mechanisms of HOXA9 regulated gene expression and 




define the genome-wide binding pattern of Hoxa9 using a murine cell line 
transformed with Hoxa9 and Meis1. De novo motif analysis reveals that Hoxa9 peaks 
are enriched with binding motifs of several transcription factors and chromatin 
modifiers, such as PU.1, C/EBP, RUNX1 and STAT5 (Huang et al., 2012). Further, 
mass spectrometry analysis identified that C/EBP and STAT5 interact with HOXA9, 
which was also confirmed by in vitro binding assays and/or co-immunoprecipitation. 
These findings support that these proteins are potential HOXA9 cofactors. The 
functional interaction between HOXA9, C/EBPΑ and PU.1 will be further explored in 
the current study.  
1.3  Function of MLL family proteins and their role in human diseases 
The MLL protein family contains five members, including MLL1 (MLL), MLL2 (chr. 
12q13.12, previously referred to as MLL4), MLL3, MLL4 (chr. 19q13.1, previously 
referred to as MLL2), and MLL5. MLL1 through MLL4 are homologous to the yeast 
methyltransferase Set1, and share structural and functional similarities, while MLL5 is 
considered to be the homolog of the yeast protein Set3/Set4 and is more different 
compared to other MLL proteins. MLL1-4 all contain multiple PHD fingers on their N 
terminus and a SET domain on their C terminus. Also, they all form a “core 
methyltransferase complex” with WD 5,  BBP5, hDP 30 and ASH2, and mediate 
methylation on histone H3K4. However, their functions are not redundant, with MLL1 




being more similar (Shilatifard, 2012). MLL1 and MLL4 both interact with MENIN 
and LEDGF on their N terminus, which is crucial for the proper recruitment of the 
complexes to target gene promoters, including HOXA genes (Dhar et al., 2012; 
Yokoyama and Cleary, 2008). On the contrary, MLL2 and MLL3 form complexes with 
UTX, PTIP, PA1 and NCOA6. Unlike MLL1 and MLL4, loss of MLL2 or MLL3 has 
little effect on the expression of HOXA genes (Wang et al., 2009b). Instead, MLL2 and 
MLL3 function as co-activator of estrogen receptor alpha, and are also involved in the 
regulation of adipogenesis and immunoglobulin class switch recombination (Lee et al., 
2009; Mohan et al., 2011; Shilatifard, 2012; Smith et al., 2011; Takahashi et al., 2011). 
Further, recent study shows that Trr, the Drosophila homolog of MLL2 and MLL3, is 
responsible for H3K4me1, suggesting the role of MLL2 and MLL3 in enhancer 
establishment.  
Figure 1.3 Structure of MLL protein complexes  
 
Figure 1.3. Structure of MLL protein complexes. All MLL proteins interact with WDR5, 
 BBP5, hDP 30 and ASH2 on their C terminus and form a “core methyltransferase complex”. 
However, MLL1 and MLL4 interact with MENIN and LEDGF on their N terminus (left), while 
MLL2 and MLL3 interact with UTC, PTIP, PA1 and ASC-2 on their N terminus (right). Blue 





Besides MLL1, mutations and chromosomal rearrangements of other MLL family 
members are also associated with malignancies and other disorders. MLL2 mutations 
have been discovered in Kabuki Syndrome, leukemia and lymphoma; mutations of 
MLL3 are associated with leukemia, colorectal cancer, pancreatic cancer; and 
mutations of MLL4 have been found in multiple solid tumors (Huntsman et al., 1999; 
Ng et al., 2010; Ruault et al., 2002; Saigo et al., 2008). Notably, like MLL1, MLL4 also 
undergoes cancer associated gene rearrangements. In one study, intronic insertions of 
hepatitis B virus (HBV) genomic sequences or chromosomal translocations on the 
MLL4 locus were found in 26 out of 42 human hepatocellular carcinoma (HCC) cases 
suggesting MLL4 fusions plays a key role in the pathogenesis of HCC (Saigo et al., 
2008).  
1.4  ECSASB (Elongin B/C-Cullin–SOCS box protein) E3 ligase complex 
Ubiquitin E3 ligases can be divided into two classes according to the mechanism of 
their function, HECT type E3 ligases and RING type E3 ligases. HECT type E3 
ligases have catalytic activity that accept the ubiquitin molecule from the E2 
conjugating enzyme and transfer it to the substrate. On the contrary, RING type E3 
ligases do not have catalytic activity, but function as a bridge that link E2 conjugating 
enzyme to the substrate. The ubiquitin molecule is directly transferred from the E2 
conjugating enzyme to the substrate. ECS
ASB 
E3 ligase is a class of RING type E3 




enzyme RBX2 on its C terminus; while on its N terminus, it interacts with the adaptor 
protein ElonginC, which dimerizes with ElonginB. ElonginC/B then interacts with an 
ASB protein, which recruits the substrate. So in this complex, the ASB proteins define 
the substrate specificity (Kohroki et al., 2005).  
Figure 1.4 Structure of ECS
ASB
 E3 ligase complex 
 
Figure 1.3. Schematic showing the structure of ECS
ASB
 E3 ligase complex. Cullin5 functions 
as a scaffold. It interacts with the E2 conjugating enzyme RBX2 on its C terminus, and with 
the adaptor protein ElonginC on its N terminus. ElonginC dimerizes with ElonginB. 
ElonginC/B then interacts with an ASB protein, which recruits the substrate. ELOB: EloginB. 
ELOC: EloginC. Ub: Ubiquitin. E2: Ubiquitin E2 conjugating enzyme. 
The ASB protein family contains 18 members (ASB1-18). The founding member 
ASB2 was discovered as a gene induced by all-trans retinoid acid (ATRA) via a 
retinoid receptor (RAR) binding element present in the ASB2 promoter. ASB2 
expression is rapidly induced during certain ATRA induced differentiation of leukemia 
cell lines, including APL cells containing the PML- A α fusion protein, as well as 




inhibition and cell differentiation (Guibal et al., 2002; Kohroki et al., 2001). Filamins A 
and B are two known targets of ASB2 (Heuze et al., 2008). ASB2 expression is also 
activated by Notch signaling, which leads to degradation of Jak2 directly and 
degradation of Jak3 and E2A indirectly by bridging the formation of a Cul1-Cul5 
dimeric E3 ligase complex (Nie et al., 2011; Wu and Sun, 2011). Besides a role in 
hematopoiesis, ASB2 can also regulate muscle differentiation (Bello et al., 2009). 
Other ASB proteins also function in various biological processes. For example, ASB3 
mediates ubiquitination and degradation of tumor necrosis factor receptor II, ASB1 
regulates spermatogenesis, and ASB15 regulates myoblasts differentiation (Chung et 
al., 2005; Heuze et al., 2005; Kile et al., 2001; McDaneld and Spurlock, 2008). In this 
study, we provide evidence that ASB2 regulates hematopoiesis by mediating MLL 








2.1  Abstract 
MLL is a key epigenetic regulator of normal hematopoietic development and 
chromosomal translocations involving MLL are one of the most common genetic 
alterations in human leukemia. Here we show that ASB2, a component of the ECS
ASB
 
E3 ubiquitin ligase complex, mediates MLL degradation through interaction with the 
PHD/Bromodomain region of MLL. Forced expression of ASB2 degrades MLL and 
reduces MLL transactivation activity. In contrast, the MLL-AF9 fusion protein does 
not interact with ASB2 and is resistant to ASB2 mediated degradation. Increased 
expression of ASB2 during hematopoietic differentiation is associated with decreased 
levels of MLL protein and down-regulation of MLL target genes. Knockdown of ASB2 
leads to increased expression of HOXA9 and delayed cell differentiation. Our data 
support a model whereby ASB2 contributes to hematopoietic differentiation, in part, 
through MLL degradation and HOX gene down-regulation. Moreover, deletion of the 
                                                 
1 This work has been published as Wang, J., Muntean, A.G., and Hess, J.L. (2012). ECSASB2 mediates MLL 




PHD/Bromo region renders MLL fusion proteins resistant to ASB2 degradation and 
likely contributes to leukemogenesis.  
 
2.2  Introduction 
The histone H3 lysine 4 (H3K4) methyltransferase Mixed Lineage Leukemia (MLL) is 
necessary for the maintenance of HOX patterning and essential for normal 
hematopoiesis. Full length MLL is a multi-domain protein that is proteolytically 
cleaved into a N-terminal fragment (MLL
N
) and a C-terminal fragment (MLL
C
) that 
non-covalently associate to form a stable complex (Hsieh et al., 2003b). MLL
N
 contains 
several DNA binding domains including three AT-hooks and a CxxC domain, as well 
as a poorly understood PHD/Bromodomain (PHD/Bromo) region that contains four 
plant homeodomain fingers (PHD1-4) and a bromodomain between PHD3 and PHD4. 
MLL
C
 contains a transactivation domain and a SET domain with intrinsic H3K4 
methyltransferase activity (Figure 2.1A). MLL mediates methylation of H3K4 and 
positively regulates target gene expression, including homeobox (HOX) genes and their 
co-factors such as MEIS1 (Wang et al., 2009b). MLL is responsible for maintaining 
expression of HOX and MEIS1 in hematopoietic stem cells and progenitors, which is 
required for stem cell self-renewal and progenitor expansion (Jude et al., 2007; 
McMahon et al., 2007; Wang et al., 2009b). HOX expression decreases concurrent with 




activation of HOX genes is associated with leukemia and other malignancies 
(Argiropoulos and Humphries, 2007).  
Chromosomal translocations involving MLL are one of the most common genetic 
alterations in human leukemia, accounting for up to ~80% of infant leukemia and about 
5-10% of adult leukemia overall (Aplan, 2006; Hess, 2004a). Most of the leukemogenic 
MLL fusion proteins contain the N-terminus of MLL fused in frame to the C-terminus 
of a translocation partner, thus forming a chimeric protein with abnormal 
transactivation ability (Hess, 2004a). Both in vitro and in vivo studies have 
demonstrated that these MLL fusion proteins induce leukemogenesis mainly through 
constitutive activation of HOXA9 and MEIS1 (Armstrong et al., 2002; Ayton and 
Cleary, 2003; Wong et al., 2007). Notably, translocations of MLL invariably occur 
within the breakpoint cluster region (BCR) which leads to the deletion or disruption of 
the PHD/Bromo region (Zhang and Rowley, 2006). Further, insertion of PHD/Bromo 
into MLL-AF9 and MLL-ENL fusion proteins abolishes their transformation ability 
suggesting this region may be important for the regulation of MLL (Chen et al., 2008; 
Muntean et al., 2008).  
The ankyrin repeat and suppressor of cytokine signaling (SOCS) box-containing (ASB) 
protein family contains 18 members (ASB1-18), which function as the substrate 
recognition module in the ECS
ASB
 (Elongin B/C-Cullin–SOCS box protein) E3 




(EloC), the ASB proteins associate with ElonginB (EloB), Cullin5 (Cul5) and Rbx2, 
and target the substrate for ubiquitination (Kohroki et al., 2005). A number of studies 
have shown that ASB proteins function in a wide range of biological processes (Chung 
et al., 2005; Heuze et al., 2005; Kile et al., 2001; McDaneld and Spurlock, 2008). ASB2 
was discovered as a gene induced by all-trans retinoid acid (ATRA) via a retinoid 
receptor (RAR) binding element present in the ASB2 promoter. ASB2 expression is 
rapidly induced during ATRA induced differentiation of leukemia cell lines, including 
APL cells containing the PML- A α fusion protein, as well as HL60 and NB4 cell 
lines, while ectopic expression of ASB2 promotes growth inhibition and cell 
differentiation (Guibal et al., 2002; Kohroki et al., 2001). Filamins A and B are two 
known targets of ASB2 (Heuze et al., 2008). ASB2 expression is also activated by 
Notch signaling, which leads to degradation of Jak2 directly and degradation of Jak3 
and E2A indirectly by bridging the formation of a Cul1-Cul5 dimeric E3 ligase 
complex (Nie et al., 2011; Wu and Sun, 2011). Besides a role in hematopoiesis, ASB2 
can also regulate muscle differentiation (Bello et al., 2009).  
In this study, we explored the function of the MLL PHD/Bromo region and identified 
ASB2 as a novel regulator of MLL stability during hematopoietic differentiation. 
 




2.3.1 Cell culture 
Human embryonic kidney 293 cells were cultured in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Hoxa9-ER cells 
were cultured in Iscove's modified Dulbecco's medium (IMDM) supplemented with 15% 
FBS (Stem Cell Technologies) and 100nM 4-OHT. NB4 and K562 cells were cultured 
in RPMI-1640 medium supplemented with 10% FBS. MLL-AF9, MLL-ENL and 
E2A-HLF cells were cultured in IMDM supplemented with 15% FBS (Stem Cell 
Technologies) and 10ng/ml IL3.  
2.3.2 Vector construction 
pCXN2-Flag-MLL, pCXN2-Flag-MLL-AF9 have been described previously (Milne et 
al., 2002).  Flag-MLL-AF9 was cloned into MSCV vector through digestion with 
restriction enzyme and ligation. CxxC, CxxC-PHD/Bromo and the deletion constructs 
were cloned from full length MLL, Flag or Myc tag and the nuclear localization signal 
were added by PCR reaction. The fragments were then ligated to MigR1 or pCMV 
vector (Clontech). pCMV-ASB2-3XFlag, pCMV-ASB6-3XFlag, 
pCMV-ASB7-3XFlag expression vectors were kindly provided by Dr. Junya Kohroki 
(Tokyo University of Science). The Flag tag was replaced with HA tag by PCR-based 
mutagenesis. ASB2 deletion constructs were cloned from pCMV-ASB2-HA and 




pcDNA5/FRT-Flag-Cullin5, and pCI-neo-ElonginC expression vectors were kindly 
provided by Dr. Joan Conaway (Stowers Institute for Medical Research).  
2.3.3 Immunoprecipitation and Western blotting 
Immunoprecipitation and western blotting were performed as described previously 
(Chen et al., 2008). 293 cells were transfected with FuGene 6 (Roche) according to the 
manufacturer's instructions and cultured for 48hrs. Cells were then lysed with BC-300 
lysis buffer (20mMTris-HCl (pH 7.4), 10% glycerol, 300mM KCl, 0.1% NP-40) and 
incubated with agarose affinity beads overnight at 4C. Beads were washed 3 times with 
BC-300 buffer. Proteins were eluted by boiling in SDS-loading buffer, resolved by 
SDS-PAGE, and detected by western blotting. Primary antibodies against MLL, ASB2, 
ElonginB, SIII p15 (ElonginC) andβ-ACTIN were obtained from Bethyl and Upstate, 
Abcam and Imgenex, Santa Cruz biotechnology, BD Transduction Laboratories, and 
Sigma respectively. Antibodies against Myc and HA tag were obtained from Abcam. 
Anti-Flag antibody and M2 anti-Flag agarose affinity beads were purchased from 
Sigma. Anti-Myc agarose affinity beads were purchased from Clontech.  
2.3.4 Protein identification by LC-Tandem Mass Spectroscopy 
293 cells were transfected with empty vector or Flag tagged CxxC or 
CxxC-PHD/Bromo. Cells were lysed and immunoprecipitations were performed as 
described above. Bound material was eluted with Flag peptide and concentrated with a 




SDS-PAGE. Mass spectroscopy analysis was performed using a LTQ-Orbitrap XL 
mass spectrometer (ThermoFisher). Proteins were identified by searching the data 
against Human IPI database (v 3.41, 72,254 entries) appended with decoy (reverse) 
sequences using X!Tandem/Trans-Proteomic Pipeline (TPP) software suite 
(Nesvizhskii et al., 2003). All proteins with a ProteinProphet probability score of >0.9 
(error rate <2%) were considered positive identifications. 
2.3.5 Dual luciferase assay 
293 cells were transfected with MLL or MLL-AF9, ASB2, Renilla luciferase reporter 
(internal control), and Hoxa9-LUC reporter with FuGene 6 according to the 
manufacturer's instructions. Cells were serum-starved in 0.5% FBS in OPTI-MEM 
media for 48 hr. Luciferase assays were performed using the Dual Luciferase Assay Kit 
(Promega) according to manufacturer's instructions. Emission was detected using a 
Monolight 3010 Luminometer (BD Biosciences). 
2.3.6 Chromatin immunoprecipitation (ChIP) 
ChIP assay was performed as described previously.(Milne et al., 2005) Antibodies 
against Flag tag and H3K4me3 were obtained from Sigma and Abcam respectively. 
Primary rabbit antibody against MLL
C
 was kindly provided by Dr. Yali Dou 
(University of Michigan). qPCR was performed on the precipitated DNAs with 




follows: ΔCT = CT(input) − CT(Chromatin IP), % total = 2
ΔCT
. Primer and probe 
sequences are listed as below.  
Primer1: Taqman Probe: CCTGCGGTGGCAACCTCAGATCC 
 Forward Primer: GCCATCAAGGCCTAATCGTG 
 Reverse Primer: AAGACCCGAAGCTCCTCCTG 
Primer2: Taqman Probe: CCCACATCGAGGGCAGGAAACACT 
 Forward Primer: CACCCGCGGCGTCTT 
 Reverse Primer: CGAACCAATGGATCTGGCA 
Primer3: Taqman Probe: TGAATTTTCCCCCTTTTGGGCCAC 
 Forward Primer: TAGACTCACAAGGACAATATCTCCTTTT 
 Reverse Primer: AGGTACTGAGTATTAAGCAGCTGTTTAC
A 
Primer4: Taqman Probe: CCACCGCCCCTCCCATTAACAACA 
 Forward Primer: CTGTTGCTTTGTGTTCCAGATTG 
 Reverse Primer: AAGTGAGAAGGCCACAGCCA 
Primer5: Taqman Probe: CCTCTTGATGTTGACTGGCGATTTTCCC 
 Forward Primer: TGACCCCTCAGCAAGACAAAC 
 Reverse Primer: TCCCGCTCCCCAGACTG 
Primer6: Taqman Probe: AAGCGCCTGGCTGGCTTTCCA 
 Forward Primer: AGGGTGATCTGGCCGATGT 
 Reverse Primer: AAAATGGGCTACCGACCCTAGT 
Primer7: Taqman Probe: TGTTGGTCGCTCCTGACTTTCCACC 
 Forward Primer: CACAGCGAGGCAAACGAAT 
 Reverse Primer: TTATTGTTTCGGAAGCCACACA 
Primer8: Taqman Probe: ATTATGACTGCAAAACACCGGGCCATT 
 Forward Primer: CGCGATCCCTTTGCATAAAA 
 Reverse Primer: CGTAAATCACTCCGCACGCT 
Primer9: Taqman Probe: CTTCAGTCCTTGCAGCTTCCAGTCCAA 
 Forward Primer: CAGCTCTGGCCGAACACC 
 Reverse Primer: TTCCACGAGGCACCAAACA 
Primer10: Taqman Probe: TACCCTCCAGCCGGCCTTATGGC 
 Forward Primer: GGTGCGCTCTCCTTCGC 
 Reverse Primer: GCATAGTCAGTCAGGGACAAAGTGT 
Primer11: Taqman Probe: CCAACTGGCTACATGCTCGCTCCA 
 Forward Primer: TCTCTCTCCCTCCGCAGATAAC 




2.3.7 Real-time quantitative reverse transcription PCR (RT-qPCR) 
RNA was extracted from cells using TRIzol reagent (Invitrogen) and cDNA was 
synthesized using Superscript III Reverse Transcriptase (Invitrogen) according to 
manufacturer’s instructions.  T-qPCR was performed with Taqman gene expression 
assays (Applied Biosystems) and ABI 7500 PCR Detection System. Data was analyzed 
using comparative ΔΔCt method (described in ABI Prism 7700 Sequence Detection 
System User Bulletin No. 2). Taqman primer probe sets for mouse Asb2, Mll, Hoxa9, 
Meis1 and human ASB2, MLL, HOXA9 and MEIS1 were purchased from Applied 
Biosystems.  
2.3.8 shRNA knockdown and Characterization of cell differentiation 
pSM2 shRNA against human ASB2 (clone ID V2HS_97797) and mouse Asb2 (clone 
ID V2MM_54107) and pTRIPZ shRNA against human ASB2 (clone ID 
V2THS_97800) were purchased from Open Biosystems. Lentiviral vector pTRIPZ 
shRNAs were packaged by the University of Michigan Vector Core. Retroviral vector 
pSM2 shRNAs were packaged in Plat-E cells as described previously(Muntean et al., 
2010). Cells were transduced by spinoculation and selected with puromycin at 0.5 
ug/ml (for Hoxa9-ER Hoxa9-ERcells) and 0.4 ug/ml (for NB4 cells).  
To evaluate cell differentiation, pTRIPZ shRNA-transduced NB4 cells were treated 
with 0.5ug/ml doxycycline for 24hrs to induce shRNA expression. Then ATRA or 




analysis, cells were collected and washed with PBS, and stained with APC-mouse 
anti-human CD11b antibody or isotype control (BD Pharmingen) for 30min. Cells were 
then washed with Standard Buffer (1X PBS, 0.1% sodium azide, 1% heat inactivated 
FBS) twice and resuspended in Standard Buffer. FACS data was collected on an LSRII 
(BD Pharmingen) and analyzed with FlowJo flow cytometry analysis software. For 
nitroblue tetrazoleum (NBT) assay, 2×10
5
 cells were suspended in 200μL medium with 
1 mg/mL NBT and 30 ng/mL 12-O-tetradecanoylphorbol-13-acetate (Sigma), and 
incubated at 37°C for 30 minutes. Cytospins were then prepared and the percentage of 
NBT positive cells was determined by microscopically counting at least 500 cells per 
experimental condition. 
2.3.9 Protein purification 
His-MBP-PHD3 (aa1551-1629) and His-MBP-PHD3-4 (aa1551-2025) were generated 
by cloning the fragments into the pMCSG9 vector (Donnelly et al., 2006). 
His-GST-ASB2 was generated by cloning ASB2-HA into pMCSG10. Expression 
plasmids were transformed into BL21 bacteria and screened at the University of 
Michigan High-Throughput Protein Lab. Bacteria were grown at 37C in TB medium at 
250 rpms with 50ug/ml spectinomycin and 100ug/ml ampicillin to an OD600 of 
approximately 0.7, and protein expression was induced with 200μM IPT  overnight at 
20C. Bacteria were lysed in CelLytic B buffer (Sigma) supplemented with 0.15M NaCl, 




and Complete protease inhibitor cocktail tablet (Roche). Proteins were purified over a 
Ni column (GE Pharmacia) using an AKTA Purifier liquid chromatography system 
(GE Pharmacia) and eluted with 20 CV of elution buffer (20mM Tris-HCl, pH 7.5, 10% 
glycerol, 1mM DTT, 0.15M NaCl, 20-500mM imidazole). For His-MBP-PHD3-4 and 
His-MBP-PHD3, secondary purification was performed using a amylose column (GE 
Pharmacia) and identical elution buffers except 0.15M-1M NaCl gradient. Purified 
proteins were visualized by Coomassie staining. For the purification of ECS
ASB2
 
complex, pCMV-ASB2-3XFlag was transfected into 293 cells using FuGene6 
according to the manufacturer's instructions and cultured for 48hrs. Cells were then 
lysed with BC-300 lysis buffer. ECS
ASB2
 complex was purified using Anti-
affinity gel (Sigma) according to the manufacturer's instructions. Proteins are eluted 
with elution buffer (20mMTris-HCl (pH 7.4), 10% glycerol, 150mM KCl, 0.1% NP-40) 
containing 150 ng/ul Flag peptides and visualized by Coomassie staining.  
2.3.10 In vitro binding assay 
Equal amounts of purified His-MBP/ His-MBP–PHD3/ His-MBP-PHD3-4 and 
His-GST/His-GST-ASB2 (1ug) were incubated in 500ul Binding Buffer (50mM 
Tris-HCl pH7.9, 100mM KCl, 0.05% NP40, 0.1% BSA) for 2 hours at 4C. 20ul 
Amylose resin (New England Biolabs) was then added to the binding buffer and 




Tris-HCl pH 7.9, 500 mM KCl, 0.3% NP40) 3 times and eluted from beads by boiling 
in SDS loading buffer. Eluted material was visualized by western blot.  
2.3.11 In vitro ubiqutination assay 
Equal amounts of purified ECS
ASB2
 and His-MBP/ His-MBP–PHD3/ 
His-MBP-PHD3-4 (1ug) were incubated with 180ng UBE1, 560ng UbcH5C, 1ug 
HA-ubiquitin and 2mM ATP in 30ul reaction butter (50mM Tris-HCl pH7.5, 5mM 
MgCl2, 2mM NaF, 0.5mM DTT) at room temperature for 3hrs. Reactions were 
terminated by adding 30ul 2X SDS sample buffer and boil for 5-10min. Western blot 
was then performed to detect ubiquitination. 
 
2.4  Results  
2.4.1 ASB2 interacts with the PHD/Bromo region of MLL 
The PHD/Bromo region of MLL is located downstream of the BCR and invariably 
deleted from MLL fusion proteins (Figure 2.1A). To elucidate its function, we 
performed mass spectroscopy to identify proteins that associate with the PHD/Bromo 
region of MLL. A Flag-tagged MLL construct that encompasses the 
CxxC-PHD/Bromo region containing a nuclear localization signal (NLS) was 
transiently expressed in human embryonic kidney 293 cells and immunoprecipitated 




SDS-PAGE and subjected to mass spectroscopy analysis. An empty vector containing 
the Flag tag and NLS, and Flag tagged CxxC with NLS were immunoprecipitated in 
parallel as controls to exclude nonspecific binding and proteins that associate with the 
CxxC domain. Multiple peptides corresponding to components of the ECS
ASB
 E3 
ubiquitin ligase complex were identified that specifically interact with 
CxxC-PHD/Bromo, including Cullin 5 (CUL5), ElonginC (ELOC) and several ASB 
proteins, such as ASB7, ASB10, ASB14 and ASB18 (Figure 2.1C).  
Figure 2.1 Identification of CxxC-PHD/Bromo binding proteins by mass 
spectroscopy  
 
Figure2.1 Identification of CxxC-PHD/Bromo binding proteins by mass spectroscopy. (A) 
Schematic diagram of the structure of wild-type MLL. The CxxC and CxxC-PHD/Bromo 
fragment used in immunoprecipitation are shown with the first and last MLL amino acid 
retained in the constructs indicated. (B) Flag tagged CxxC or CxxC-PHD/Bromo was 




CxxC, CxxC-PHD and co-eluted proteins. (C) Summary of components of the ECS
ASB
 complex 
identified by mass spectroscopy that specifically interact with CxxC-PHD/Bromo but not 
CxxC. 
The ASB protein family contains 18 members. As multiple ASB proteins were 
identified by mass spectroscopy, we focused our attention on ASB2 because of its 
specific activity against MLL protein (see below) and known roles in hematopoiesis. 
ASB2 is expressed in hematopoietic cells and has been shown to promote both 
differentiation and cell cycle arrest in certain myeloid leukemia cell lines, consistent 
with a function in hematopoiesis (Guibal et al., 2002; Kohroki et al., 2001). To test the 
interaction between the PHD/Bromo region and the ECS
ASB2
 complex, Myc-tagged 
CxxC or CxxC-PHD/Bromo and HA tagged ASB2 were coexpressed in 293 cells in the 
presence of the proteasome inhibitor MG132. ASB2 co-precipitated specifically with 
CxxC-PHD/Bromo but not CxxC confirming an interaction dependent on the 
PHD/Bromo region. Moreover, endogenous ELOB and ELOC also co-precipitated 
with CxxC-PHD/Bromo (Figure 2.2A). To determine if MLL and ASB2 interact under 
physiological conditions, NB4 cells were treated with ATRA to induce ASB2 
expression and with MG132 to inhibit MLL degradation. Immunoprecipitation of 
endogenous MLL showed that ASB2 co-precipitated with MLL, further supporting a 
physiological interaction in hematopoietic cells (Figure 2.2B). As MLL fusion proteins 
generally lack the PHD/Bromo region, we tested if the interaction is disrupted in the 
context of MLL-AF9 by co-expressing MLL or MLL-AF9 with ASB2 in 293 cells. 




suggesting the PHD/Bromo region is necessary for ASB2 interaction with MLL (Figure 
2.2C). Based on these observations, we predicted that ubiquitination of MLL would be 
at least partially dependent on the presence of the PHD/Bromo region. To this end, 
CxxC or CxxC-PHD/Bromo was coexpressed with ubiquitin in 293 cells. 
Immunoprecipitation revealed an ubiquitin smear associated with the 
CxxC-PHD/Bromo but not the CxxC domain alone (Figure 2.2D). These data indicate 
that the PHD/Bromo region interacts with the ECS
ASB2
 E3 ubiquitin ligase and results 
in the ubiquitination of MLL.  






Figure 2.2. PHD/Bromo region interacts with ASB2 and mediates MLL ubiquitination. (A) 
Myc tagged CxxC or CxxC-PHD/Bromo (CxxC-P/B) was coexpressed in 293 cells with HA 
tagged ASB2. Cells were treated with MG132 for 6hrs. Immunoprecipitation of CxxC or 
CxxC-PHD/Bromo followed by western blotting shows that ASB2 and endogenous ELOB and 
ELOC specifically interact with CxxC-PHD/Bromo. (B) NB4 cells were treated with ATRA 
for 48hrs and with MG132 for 16hrs. MLL was immunoprecipitated with an anti-MLL 
antibody, and western blotting using an anti-ASB2 antibody shows that endogenous ASB2 
co-precipitates with MLL. (C) Flag tagged MLL or MLL-AF9 was coexpressed in 293 cells 
with HA tagged ASB2. After MG132 treatment, anti-Flag immunoprecipitation was performed 
followed by western blotting, showing that ASB2 interacts with MLL but not with MLL-AF9. 
(D) Myc tagged CxxC or CxxC-PHD/Bromo and Flag tagged ubiquitin were coexpressed in 
293 cells. Immunoprecipitation of CxxC or CxxC-PHD/Bromo was performed after MG132 
treatment. Western blotting shows that CxxC-PHD/Bromo is conjugated with ubiquitin. 
2.4.2 ASB2 degrades MLL and reduces MLL transactivation ability 
To test the effect of ASB2 on MLL protein turnover, full length MLL was coexpressed 
in 293 cells with ASB2 or two other ASB proteins, ASB6 and ASB7. Western blotting 
with whole cell lysate revealed that overexpression of ASB2 led to significant 
degradation of MLL, while overexpression of ASB6 and ASB7 did not affect MLL 
protein levels (Figure 2.3A). The effect of ASB2 was also confirmed on endogenous 
MLL as ASB2 expression in 293 cells led to reduced endogenous MLL protein level 
detected by western blotting (Figure 2.3B). Because ASB2 interacts with wild-type 
MLL but not MLL-AF9 fusion protein (Figure 2.2C), we predicted that overexpression 
of ASB2 would degrade MLL while largely not affecting MLL-AF9 protein levels. To 
test this, equimolar amounts of plasmids expressing MLL or MLL-AF9 were 
cotransfected into 293 cells with an increasing dosage of ASB2. Western blotting 
revealed that ASB2 led to degradation of MLL in a dose-dependent manner, while the 




Figure 2.3 ASB2 expression reduces MLL protein level 
 
Figure 2.3. ASB2 expression reduces MLL protein level.  (A) MLL was coexpressed with Flag 
tagged ASB2, ASB6 and ASB7 in 293 cells. Western blotting with whole cell lysate shows that 
ASB2 specifically degrades MLL. β-ACTIN blot shows equal loading of the samples. (B) 
Expression of ASB2 in 293 cells followed by western blotting with whole cell lysate shows that 
ASB2 leads to degradation of endogenous MLL. (C) Equimolar amounts of MLL or MLL-AF9 
expression plasmids were cotransfected with ASB2 at the ratio of 6:1, 2.5, 4 in 293 cells. 
Western blotting with whole cell lysate shows that MLL degradation is ASB2 dose-dependent, 
while the level of MLL-AF9 is not affected. β-ACTIN blot indicates equal loadings. 
As ASB2 functions in the ECS
ASB
 E3 ligase complex that contains multiple subunits, 
we tested the effect of the other components on the stability of MLL and MLL-AF9. 
ELOB, ELOC or CUL5 was coexpressed with MLL or MLL-AF9 in 293 cells. Western 
blotting with whole cell lysate revealed that CUL5 did not affect MLL stability and 
ELOB and ELOC had a limited effect on the degradation of MLL (Figure 2.4A, left 
panel), demonstrating the importance of substrate recognition by ASB2. In contrast, the 




Figure 2.4 The effect of other ECSASB2 E3 ligase complex components on the 
stability of MLL and MLL-AF9 
 
Figure 2.4. The effect of other ECS
ASB
 E3 ligase complex components on the stability of MLL 
and MLL-AF9.  (A) HA tagged ASB2, Flag tagged ELOB, Flag tagged CUL5 or ELO C was 
cotransfected into 293 cells with MLL or MLL-AF9. Western blotting with whole cell lysate 
shows that ASB2 led to degradation of MLL. ELOB and ELOC led to degradation of MLL to a 
lesser extent. CUL5 did not affect the stability of MLL. None of the components have a 
significant effect on the stability of MLL-AF9. 
Next, we examined the effect of ASB2 on MLL mediated transcriptional 
transactivation. Dual luciferase assays were performed with a firefly luciferase reporter 
driven by the murine Hoxa9 promoter (Hoxa9-LUC reporter) (Figure 2.5A). 
Expression of MLL led to a greater than 7-fold activation of reporter expression (Figure 
2.5B, lane3). While ASB2 alone had no effect on reporter expression, coexpressed 
ASB2 reduced MLL mediated transactivation on the Hoxa9-LUC reporter in a 
dose-dependent manner (Figure 2.5B, lane 2 and 4-6). Only a slight decrease in the 




2.5B, lane 7-10). We also tested the recruitment of MLL to the promoter region of 
Hoxa9-LUC upon expression of ASB2. 293 cells were transfected with MLL, ASB2 
and the Hoxa9-LUC reporter, and a chromatin immunoprecipitation (ChIP) assay was 
performed with probes that specifically recognize the murine Hoxa9 promoter (Figure 
2.5A). Consistent with the luciferase assay, MLL showed robust binding to the Hoxa9 
promoter, which decreased to background levels upon expression of ASB2 (Figure 
2.5C).  
Figure 2.5 ASB2 expression leads to reduced MLL transactivation ability 
 
Figure 2.5. ASB2 expression leads to reduced MLL transactivation ability. (A) Schematic 
diagram of the Hoxa9-LUC reporter. (B) Dual luciferase assay was performed in 293 cells with 
Hoxa9-LUC reporter. Lane 3-6 shows expression of MLL with increasing dosage of ASB2, and 
lanes 7-10 shows expression of MLL-AF9 with increasing dosage of ASB2. The ratios between 
MLL or MLL-AF9 and ASB2 were the same as in (Figure 2.3 C). All changes are normalized to 




standard deviation. Results of one of more than three representative experiments performed are 
shown. (C) ChIP assay was performed in 293 cells transfected with Hoxa9-LUC, MLL and 
ASB2. The ratio between MLL and ASB2 was 6:4. Probes 4-8 cover the promoter region of 
Hoxa9-LUC. Probe3 recognizes a region that exists in the endogenous Hoxa9 promoter but is 
not included in Hoxa9-LUC, and serves as a negative control. The nomenclature is consistent 
with Figure 2.21A, which shows the position of the probes on endogenous Hoxa9 locus. Error 
bars indicate standard deviation. Results of one of more than three representative experiments 
performed are shown. 
2.4.3 The bromodomain and 4th PHD finger of MLL mediate interaction with 
ASB2 
The PHD/Bromo region of MLL contains four PHD fingers (PHD1-4) and an atypical 
bromodomain between PHD3 and PHD4 (Figure 2.1A). To further characterize the 
MLL-ASB2 interaction and identify which part of the PHD/Bromo region mediates the 
interaction with ASB2, we made a series of deletion constructs spanning the 
CxxC-PHD/Bromo region (Figure 2.6A), and performed co-immunoprecipitation 
experiments with full-length ASB2. Deletion beyond the bromodomain led to 
disruption of the MLL-ASB2 interaction (Figure 2.6B). A more robust interaction was 
observed when PHD4 was included (Figure 2.6B compare lane 7 and 8) suggesting that 




Figure 2.6 The Bromodomain/PHD4 of MLL mediates interaction with ASB2 
 
Figure 2.6. The Bromodomain/PHD4 of MLL mediates interaction with ASB2. (A) Schematic 
diagram of the CxxC-PHD/Bromo serial deletions. The first and last MLL amino acid retained 
in the constructs are indicated. (B) CxxC-PHD/Bromo deletion constructs described in (A) 
were cotransfected with ASB2 into 293 cells followed by anti-Myc immunoprecipitation. 
Binding of ASB2 was detected by western blotting with anti-HA antibody.  
Consistent with this, MG132 treatment led to stabilization of the two deletion proteins 
containing Bromo or Bromo-PHD4, supporting that this region is important for 




Figure 2.7 Bromodomain/PHD4 containing fragments are stabilized by MG132 
 
Figure 2.7. Bromodomain/PHD4 containing fragments are stabilized by MG132. (A). 
CxxC-PHD/Bromo deletion constructs described in (Figure 2.6A) were cotransfected with 
ASB2 into 293 cells followed by MG132 or DMSO treatment for 16hrs. Western blotting with 
whole cell lysate shows that CxxC-PHD123-Bromo and CxxC-P/B were stabilized by MG132 
(lanes 7 and 8 in each blot). 
To investigate whether MLL and ASB2 directly associate, in vitro binding assays were 
performed with bacterially expressed and purified His-GST tagged ASB2-HA and 
His-MBP tagged PHD3-Bromo-PHD4 (PHD3-4). ASB2 specifically bound to PHD3-4, 
but not to PHD3, suggesting a direct interaction (Figure 2.8A-B). In addition, to test if 
Bromo-PHD4 can serve as a substrate of ASB2, in vitro ubiquitination assays were 
performed with immunopurified ECS
ASB2
 complex from 293 cells and 
bacterially-purified His-MBP-PHD3-4. Purified ECS
ASB2
 complex showed 
ATP-dependent auto-ubiquitination activity in vitro (Lane 2, Figure 2.8C). An 






 requires the Bromo/PHD4 region of MLL for ubiquitination in 
vitro (Figure 2.8C).  
Figure 2.8 ASB2 binds to and ubiquitinates PHD3-4 in vitro 
 
Figure 2.8. ASB2 binds to and ubiquitinates PHD3-4 in vitro. (A). Coomassie staining of 
purified His-MBP, His-MBP-PHD3, His-MBP-PHD3-4, His-GST, His-GST-ASB2 and 
ASB2-Flag. 1ug His-MBP, His-MBP-PHD3 and His-GST, 2ug of His-MBP-PHD3-4, 




Bacterially purified His-GST tagged ASB2 was incubated with His-MBP tagged PHD3 or 
PHD3-4, followed by pull-down using Amylose resin. Western blotting shows that ASB2 
interacts with PHD3-4 but not with PHD3 alone. (C). Immunopurified ECS
ASB2
 complex from 
293 cells was incubated with bacterially purified His-MBP tagged PHD3 or PHD3-4 in the 
presence of UBE1 (E1), UbcH5C (E2) and HA tagged ubiquitin. Western blotting using HA 
antibody shows that an ubiquitin smear was formed with PHD3-4 but not with PHD3 
ASB2 contains 12 N-terminal ankyrin repeats which mediate protein-protein 
interactions, and a C-terminal SOCS box, which is necessary for the interaction with 
ELOC (Heuze et al., 2005). To map the interaction region on ASB2, we made serial 
deletions of ASB2 that contain different numbers of ankyrin repeats (Figure 2.9A). 
Co-immunoprecipitation experiments with Myc-CxxC-PHD/Bromo showed that the 
first five ankyrin repeats are sufficient for the interaction with MLL (Figure 2.9B). 
Figure 2.9 The N terminal five ankyrin repeats of ASB2 mediate interaction with 
MLL 
 
Figure 2.9. The N terminal five ankyrin repeats of ASB2 mediate interaction with MLL. (A) 
Schematic of HA tagged ASB2 serial deletions. The first and last ASB2 amino acid retained in 
the constructs are indicated. (B) ASB2 deletion constructs described in (A) were cotransfected 
with Myc-CxxC-PHD/Bromo in 293 cells followed by anti-Myc immunoprecipitation. Binding 




2.4.4 Increased ASB2 expression during hematopoietic differentiation is 
associated with decreased MLL protein level and MLL target gene 
expression 
Previous studies have shown that ASB2 expression is up-regulated during 
differentiation of myeloid leukemia cell lines and that ectopically expressed ASB2 
induces myeloid growth arrest and differentiation (Guibal et al., 2002; Kohroki et al., 
2001). To further explore the biological significance of MLL regulation by ASB2, we 
examined the levels of ASB2, MLL and MLL target genes during differentiation in 
both human and murine leukemia cell lines. First, the human leukemia NB4 cell line 
was treated with ATRA to induce cell differentiation. Consistent with previous 
publications (Kohroki et al., 2001). we observed a significant increase of ASB2 
expression upon ATRA treatment (Figure 2.10A). MLL protein levels decreased 
gradually and coordinately with ASB2 up-regulation (Figure 2.10B). Notably, MLL 
transcription did not significantly change with differentiation as examined by 
RT-qPCR (Figure 2.10C), indicating the decrease in MLL protein is 
post-transcriptional. RT-qPCR was also performed to test the expression levels of 
HOXA9, a major target of MLL, which decreased approximately 40% after 72 hours’ 




Figure 2.10 ASB2 expression leads to MLL degradation and MLL target gene 
down-regulation during differentiation of NB4 cells 
 
Figure 2.10. ASB2 expression leads to MLL degradation and MLL target gene down-regulation 
during differentiation of NB4 cells. (A-D) NB4 cells were treated with ATRA for 0, 48 and 
72hrs to induce differentiation. The expression of ASB2 (A), the protein level (B) and 
transcription level (C) of MLL, and the expression of HOXA9 (D) were measured by RT-qPCR 
or western blotting. Transcription is shown relative to the level at 0 hr. Error bars indicate 
standard deviation. β-ACTIN blot indicates equal loading. 
The expression of ASB2, MLL and another MLL target gene, MEIS1, was examined in 
ATRA treated K562 leukemia cells. Similar to NB4 cells, ASB2 expression increased 
during ATRA induced cell differentiation, along with decreased MLL protein level and 
MEIS1 expression, while the transcription of MLL did not change significantly (Figure 




Figure 2.11 ASB2 expression leads to MLL degradation and MLL target gene 
down-regulation during differentiation of K562 cells 
 
Figure 2.11. ASB2 expression leads to MLL degradation and MLL target gene down-regulation 
during differentiation of K562 cells. (A-E) K562 cells were treated with ATRA for 0, 48 and 
72hrs to induce differentiation. The protein level and transcription level of ASB2 (A-B), MLL 
(C-D), and the expression of MEIS1 (E) were measured by western blotting or RT-qPCR. 
Transcription is shown relative to the level at 0hr. Error bars indicate standard deviation. 
Β-ACTIN indicates equal loading. 
Because ATRA has a wide range of biological effects, we examined if the 
down-regulation of HOXA9 and MEIS1 is a direct consequence of ASB2 expression. 
To test this, ASB2 was transfected into NB4 cells and K562 cells by electroporation. 
ASB2 expression led to a significant decrease of HOXA9 expression in NB4 cells 
(Figure 2.12A-B) and MEIS1 expression in K562 cells (Figure 2.12C) suggesting the 




Figure 2.12 ASB2 expression down-regulates expression of HOXA9 and MEIS1 
 
Figure 2.12. ASB2 expression down-regulates expression of HOXA9 and MEIS1. (A-B) ASB2 
expression vector was transfected into NB4 cells by electroporation, and the expression levels 
of ASB2 (A) and HOXA9 (B) were measured by RT-qPCR. Expression is shown relative to 
empty vector transfected control cells. Error bars indicate standard deviation. (C) ASB2 
expression vector was transfected into K562 cells by electroporation, and the expression levels 
of ASB2 (Black bar) and MEIS1 (Grey bar) were measured by RT-qPCR. For visualization, 
expression of ASB2 is shown relative to empty vector transfected control cells, and MEIS1 
expression is shown relative to ASB2 transfected cells. Error bars indicate standard deviation. 
Asb2 expression was also examined in a differentiation system utilizing murine bone 
marrow cells transformed with an inducible Hoxa9-estrogen receptor (Hoxa9-ER) 
construct and maintained in 4-hydroxytamoxifen (4-OHT). Withdrawal of 4-OHT 
causes Hoxa9-ER translocation to the cytoplasm leading to cell differentiation and cell 
cycle arrest, which is largely complete within 5 days (Muntean et al., 2010). Microarray 
gene expression profiling was previously performed on Hoxa9-ER cells in the presence 
of 4-OHT and at 72, 96 and 120 hours post 4-OHT withdrawal (Muntean et al., 2010), 
and the 18 Asb family members were clustered according to their expression level 
changes. Of these, Asb2 was the most highly up-regulated gene upon differentiation 




protein level at both 72 and 120hrs post 4-OHT withdrawal compared to cells grown in 
the presence of 4-OHT independent of changes in Mll transcription (Figure 2.13C and 
D). Moreover, multiple Mll target genes, including E2f1, Rbl, Meis1 and Pbx3 were 
down-regulated consistent with up-regulated Asb2 degrading Mll protein (Figure 
2.13E).  
Figure 2.13 ASB2 expression leads to MLL degradation and MLL target gene 
down-regulation during differentiation of Hoxa9-Meis1 transformed murine cells  
 
Figure 2.13. ASB2 expression leads to MLL degradation and MLL target gene down-regulation 
during differentiation of Hoxa9-Meis1 transformed murine cells. (A-E) Expression of Asb2, 
Mll and Mll target genes during 4-OHT withdrawal induced differentiation of the 




collected at different time points after 4-OHT withdrawal. The Asb genes were clustered 
according to their expression change. Data are shown in triplicate for each time point. (B) 
Expression of Asb2 was measured by RT-qPCR at different time points during 4-OHT 
withdrawal induced differentiation of Hoxa9-ERHoxa9-ER cells, confirming the results 
obtained by microarray. Error bars indicate standard deviation. (C) Mll protein level in 
Hoxa9-ERHoxa9-ER cells was determined by western blotting at 72 and 120hrs with or 
without 4-OHT withdrawal. (D) Expression of Mll was measured by RT-qPCR at 72 and 120hr 
with or without 4-OHT withdrawal in Hoxa9-ERHoxa9-ER cells. Expression is shown relative 
to cells without 4-OHT withdrawal. No significant change was observed. Error bars indicate 
standard deviation. (E) Heat map of the Mll target gene expression generated from gene 
expression array data as in (A). 
To further evaluate the role of ASB2 on MLL target gene expression and cell 
differentiation, we generated stable NB4 cells expressing an inducible pTRIPZ shRNA 
construct against ASB2 for knockdown studies. Following doxycycline treatment, 
shRNA expression was activated, which was reflected by expression of red fluorescent 
protein (RFP) on the pTRIPZ vector, leading to knockdown of ASB2 (Figure 
2.14A-B).  
Figure 2.14 Confirmation of shRNA mediated knockdown of ASB2 
 
Figure 2.14. Confirmation of shRNA mediated knockdown of ASB2. (A) Image of NB4 cells 
transduced with pTRIPZ shRNA against ASB2 with (left) or without (right) doxycycline 
treatment for 24hrs, showing the activation of the shRNA. (B) RT-qPCR confirmation of ASB2 
knockdown in NB4 cells after doxycycline treatment for 24hrs. Expression is shown relative to 




With ASB2 knockdown, we observed an increase in MLL protein level, and a 60% 
up-regulation of HOXA9 expression (Figure 2.15A and C). Further, MLL turnover was 
monitored using NB4 cells treated with cycloheximide. Prolonged MLL degradation 
was observed in ASB2 knockdown cells compared to control scrambled 
shRNA-transduced cells (Figure 2.15C).  
Figure 2.15 ASB2 knockdown leads to stabilized MLL and increased expression 
of HOXA9 
 
Figure 2.15. ASB2 knockdown leads to stabilized MLL and increased expression of HOXA9. 
(A) Protein level of MLL was detected by western blotting with whole cell lysate, which shows 
an increase after doxycycline induced ASB2 knockdown. (B) Expression of HOXA9 was 
measured by RT-qPCR after doxycycline induced ASB2 knockdown. Expression is shown 
relative to scrambled shRNA-transduced control cells. Error bars indicate standard deviation. 
(C) NB4 cells were treated with cycloheximide for different time periods as indicated to block 
translation. The turnover of MLL was monitored by western blotting using whole cell lysate. 
MLL degradation was prolonged in ASB2 knockdown cells compared to control cells. 
The effect of ASB2 on cell differentiation was determined by monitoring the CD11b 




treatment. ASB2 knockdown led to a delay in ATRA-induced NB4 cell differentiation, 
as lower CD11b expression and a lower percentage of NBT positive cells was detected 
in ASB2 knockdown cells at both 24 and 48 hours (Figure 2.15A and B). We also 
observed that ASB2 knockdown resulted in faster growth compared to cells expressing 
control shRNA. Moreover, ATRA treatment led to a rapid growth arrest in control cells, 
while ASB2 knockdown cells retained the ability to grow, albeit at a slower rate (Figure 
2.15C).  
Figure 2.16 ASB2 knockdown inhibits cell differentiation 
 
Figure 2.16. ASB2 knockdown inhibits cell differentiation. (A-C) NB4 cells were treated with 
doxycycline for 24hrs to induce ASB2 knockdown and then with ATRA to induce 
differentiation. (A) Expression of CD11b was determined by flow cytometry at 24 and 48hrs. 
(B) NBT assay was performed at 24 and 48hrs and the percentage of positive cells is shown. 
Error bars indicate standard deviation calculated from 3 independent experiments. (C) Control 
and ASB2 knockdown NB4 cells were grown in liquid culture with or without ATRA treatment. 
A proliferation advantage was observed from ASB2 knockdown cells in both conditions. Error 




As further confirmation, a constitutive pSM2 shRNA targeting another region of ASB2 
was stably transduced into NB4 cells. Similar up-regulation of HOXA9 was observed 
with ASB2 knockdown (Figure 2.17A and B). 
Figure 2.17 ASB2 knockdown with a second shRNA leads to increased expression 
of HOXA9 
 
Figure 2.17. ASB2 knockdown leads to increased expression of HOXA9. (A) RT-qPCR 
confirmation of ASB2 knockdown with pSM2 shRNA against ASB2 in NB4 cells. Expression 
is shown relative to scrambled shRNA-transduced control cells. Error bars indicate standard 
deviation. (B) Expression of HOXA9 was measured by RT-qPCR with ASB2 knockdown. 
Expression is shown relative to scrambled shRNA-transduced control cells. Error bars indicate 
standard deviation. 
2.4.5 ASB2 reduced colony formation ability of MLL fusion transformed cells 
Previous studies showed that expression of wild-type MLL is required for MLL fusion 
protein-mediated transformation (Thiel et al., 2010). As our data suggests that ASB2 
leads to efficient degradation of MLL, we predicted that ASB2 expression would 
diminish MLL fusion mediated transformation through degradation of wild-type MLL. 
To test this, we established a murine cell line transformed with Flag tagged MLL-AF9. 
ASB2 was cloned into the MigR1 retroviral expression vector, and transduced into 




to green fluorescent protein (GFP) expression on the MigR1 vector, and colony 
formation ability was examined by methylcellulose replating assays. ASB2 expression 
led to a more than 60% decrease in colony number compared to empty 
vector-transduced control cells (Figure 2.18A-C), as well as reduced cell proliferation 
in liquid culture (Figure 2.18D). Consistent with this, a 40% decrease of Hoxa9 
expression was observed in ASB2-transduced cells compared to vector control (Figure 
2.18E), despite no detectable change in Mll transcription (Figure 2.18F).  






Figure 2.18. ASB2 reduces colony formation of MLL-AF9 transformed cells. (A) ASB2 
expression in MLL-AF9 cells was confirmed by RT-qPCR. Expression is shown relative to 
empty vector transduced control cells. Error bars indicate standard deviation. (B) Colony 
numbers of MLL-AF9 cells transduced with empty vector or ASB2 from methylcellulose 
replating assay. Error bars indicate standard deviation from three independent experiments. (C) 
P-iodonitro-tetrazolium violet staining of the colonies. (D) MLL-AF9 cells transduced with 
empty vector or ASB2 were grown in liquid culture. Significantly reduced cell proliferation 
was observed from ASB2-transduced cells. Error bars indicate standard deviation. (E) 
RT-qPCR was performed to measure the expression of Hoxa9 in MLL-AF9 cells transduced 
with empty vector or ASB2. Expression is shown relative to empty vector-transduced control 
cells. Error bars indicate standard deviation. (F) Transcription of Mll was measured by 
RT-qPCR, which did not show significant change. Expression is shown relative to empty 
vector-transduced control cells. Error bars indicate standard deviation. 
Notably, an ASB2 construct containing a deletion of the SOCS box (ASB2ΔSOCS) 
still led to degradation of MLL, a phenomenon similar to that reported for ASB4 (Li et 
al., 2007), and led to decreased colony formation when expressed in MLL-AF9 cells 
(Figure 2.19).  





Figure 2.19. ASB2ΔSOCS does not rescue colony formation of MLL-AF9 cells. (A). 
HA-tagged ASB2 or ASB2 with deletion of the SOCS box (ASB2dSOCS) was cotransfected 
into 293 cells with MLL. Western blotting with whole cell lysate shows that both ASB2 and 
ASB2dSOCS led to degradation of MLL to a similar extent. (B-D) Colony numbers (B), colony 
staining (C) and proliferation (D) of MLL-AF9 cells transduced with empty vector, ASB2 or 
ASB2dSOCS. Both ASB2 and ASB2dSOCS led to decreased colony formation and cell 
proliferation. MA: MLL-AF9. 
Decreased colony formation and cell proliferation was also observed using MLL-ENL 
cells transduced with ASB2 (Figure 2.20A-C). Importantly, expression of ASB2 in 
E2A-HLF cells, which transform in an MLL and Hoxa9 independent manner, had no 
effect on either colony formation or cell proliferation, indicating that the effect of 




Figure 2.20 ASB2 reduces colony formation in MLL-ENL transformed cells but 
not in E2A-HLF transformed cells 
 
Figure 2.20. ASB2 reduces colony formation in MLL-ENL transformed cells but not in 
E2A-HLF transformed cells. (A) Colony numbers of MLL-ENL cells transduced with empty 
vector or ASB2 from methylcellulose replating assay. Error bars indicate standard deviation 
from duplicate experiments. Results of one of more than three representative experiments 
performed are shown. (B) P-iodonitro-tetrazolium violet staining of the colonies. (C) 
MLL-ENL cells transduced with empty vector or ASB2 were grown in liquid culture. Reduced 
cell proliferation was observed from ASB2 transduced cells. Error bars indicate standard 
deviation. (D-F) Colony numbers (D), colony staining (E), and proliferation (F) of E2A-HLF 
cells transduced with empty vector or ASB2. No decrease in colony formation or cell 
proliferation was observed. Results of one of more than three representative experiments 
performed are shown. Error bars indicate standard deviation. ME: MLL-ENL, EH: E2A-HLF. 
To further confirm that the effect of ASB2 on colony formation is through wild-type 
Mll degradation, we examined the recruitment of Mll and MLL-AF9 to the Hoxa9 
locus. ChIP assays were performed with a series of probes spanning the Hoxa9 




was determined using an Mll antibody that recognizes a region that is lost in MLL-AF9 
fusion protein. Mll showed a robust binding to the Hoxa9 locus in control cells, while 
the binding was significantly reduced upon ASB2 expression (Figure 2.21B). 
Consistent with this, histone H3 lysine 4 tri-methylation (H3K4me3) is reduced in 
ASB2-transduced cells compared to control cells (Figure 2.21C). In contrast, 
recruitment of MLL-AF9, which was detected using Flag antibody, did not change 
significantly with ASB2 expression (Figure 2.21D). These data indicate that ASB2 
reduces the amount of wild-type Mll at target genes critical for leukemia, but does not 
alter MLL-AF9 fusion protein binding. 
Figure 2.21 ASB2 expression reduces recruitment of wild-type MLL but not 
MLL-AF9 to target gene loci 
 
Figure 2.21. ASB2 expression reduces recruitment of wild-type MLL but not MLL-AF9 to 
target gene loci. (A) Schematic diagram showing the endogenous Hoxa9 locus and probes used 




the recruitment of Mll (B), the H3K4me3 level (C) and the recruitment of MLL-AF9 (D) on the 
Hoxa9 locus with probes shown in (A). Antibodies against MLL, H3K4me3 and Flag were 
used respectively. Blue lines are data from MLL-AF9 cells transduced with empty vector; red 
lines are data from MLL-AF9 cells transduced with ASB2; grey lines are IgG controls for each 
cell line. Error bars indicate standard deviation. 
 
2.5  Discussion 
Post-translational modifications, such as phosphorylation, ubiquitination and 
acetylation, provide a rapid and flexible way to regulate protein activity in response to 
intrinsic and extrinsic cellular signals. As one of the major mechanisms of controlling 
protein abundance, ubiquitination has been shown to regulate a wide range of 
biological processes, including cell cycle progression, cell proliferation and 
differentiation. Recent studies have shown that several histone-modifying enzymes are 
regulated through ubiquitination. For example, the E3 ligase CUL4-DDB1 regulates 
the histone H4K20 monomethylase PR-Set7/Set8 during S phase, which is important 
for replication licensing, cell cycle progression and DNA damage response (Abbas et 
al., 2010; Centore et al., 2010; Oda et al., 2010; Tardat et al., 2010). Moreover, two 
components of the MLL complex, WDR5 and RBBP5, have been shown to be 
regulated by CUL4-DDB1, suggesting a strict regulation of H3K4 trimethylation by E3 
ubiquitin ligases (Higa et al., 2006). Indeed, previous studies have shown that MLL 









genotoxic stress disrupts the interaction with SCF
Skp2
, linking MLL to the mammalian 
S phase checkpoint (Liu et al., 2007a; Liu et al., 2010).  
In this study, we identified ASB2 as a novel regulator of MLL, and linked HOX gene 
down-regulation during hematopoiesis to MLL ubiquitination and degradation through 
the ECS
ASB2
 ubiquitin ligase complex. ASB2 expression leads to degradation of MLL 
and reduces its transactivation ability (Figure 2.3 and 2.5). A significant increase in 
ASB2 expression was observed during differentiation of both human leukemia (NB4 
and K562) cell lines and murine leukemia (Hoxa9-ER) cell line, displaying a reciprocal 
pattern to the MLL protein level and MLL target gene expression (Figure 2.10-2.13). 
Furthermore, expression of ASB2 leads to HOXA9 and MEIS1 down-regulation, while 
knockdown of ASB2 up-regulates HOXA9 and renders the cells resistant to 
differentiation stimuli (Figure 2.10-2.17). These findings support a model where MLL 
is regulated post-translationally through ASB2 up-regulation during hematopoietic 
differentiation leading to an active ECS
ASB2
 E3 ubiquitin ligase complex that rapidly 
degrades MLL protein and down-regulates HOX gene (Figure 2.22A-B). In contrast, 
loss of the PHD/Bromo region and escape from ASB2 mediated degradation may 
contribute to MLL fusion mediated leukemogenesis (Figure 2.22C). Our study adds to 




 act coordinately to 
control MLL protein turnover during cell cycle progression, while ECS
ASB2
 regulates 




protein turnover is tightly controlled by several E3 ubiquitin ligase complexes during 
various biological processes. 
Figure 2.22 Model for the regulation of MLL degradation and HOX gene 
expression by ASB2 during normal and malignant hematopoiesis 
 
Figure 2.22. Model for the regulation of MLL degradation and HOX gene expression by ASB2 
during normal and malignant hematopoiesis. (A) In hematopoietic stem cell and progenitor 
compartments, MLL maintains HOX gene expression. (B) During differentiation, ASB2 
expression is induced, which leads to MLL ubiquitination and degradation. Less MLL is 
localized to HOX gene loci, resulting in inhibition of HOX gene transcription. (C) In MLL 
fusion protein-mediated leukemias, MLL fusion proteins lack the PHD/Bromo region that 
interacts with ASB2 and escape from ASB2-mediated degradation. Moreover, low expression 
of ASB2 leads to stabilization of wild-type MLL, which may also contribute to the constitutive 




Our experiments show that the interaction between ASB2 and MLL is mediated 
through the PHD/Bromo region (Figure 2.6 and 2.8). This region contains four PHD 
fingers and a bromodomain between PHD3 and PHD4. The third PHD finger of MLL 
has been reported to bind di/tri-methylated histone H3K4 as well as the cyclophilin 
Cyp33 simultaneously, switching MLL from an activator to a repressor (Chang et al., 
2010b; Hom et al., 2010; Park et al., 2010; Wang et al., 2010). and loss of MLL PHD3 
is required for MLL-ENL mediated transformation (Chen et al., 2008). The first and 
fourth PHD finger function together with the phenylalanine/tyrosine-rich (FYRN) 





(Yokoyama et al., 2011). In our experiments, inclusion of the bromodomain is 
sufficient to mediate the interaction with ASB2, while the addition of PHD4 enhances 
binding (Figure 2.6). A number of bromodomains have been demonstrated to mediate 
protein-protein interaction through recognizing acetylated lysines (Sanchez and Zhou, 
2009). Interestingly, although exhibiting a typical bromodomain fold, the 
bromodomain of MLL does not recognize acetylated histones, perhaps due to loss of a 
conserved asparagine found in acetyl-lysine binding bromodomains (Wang et al., 2010). 
Moreover, a sequence analysis of various human bromodomains defines the MLL 
bromodomain as an outlier, because of significant sequence variation (Sanchez et al., 
2000; Sanchez and Zhou, 2009). Further work is needed to determine if the interaction 





A recent study reports that the wild-type allele of MLL is required for MLL-AF9 
mediated leukemogenesis. Wild-type Mll is recruited to the Hoxa9 locus in MLL-AF9 
transformed cells, and plays a crucial role for the maximal methylation of both H3K79 
and H3K4, as well as the expression of Hoxa9. Knockdown or excision of wild-type 
Mll in MLL-AF9 transduced cells inhibits cell proliferation, reduces colony formation 
and inhibits the development of leukemia in vivo (Thiel et al., 2010). Based on these 
observations, the authors propose that MLL fusion transformed leukemia cells may be 
more sensitive to inhibition of wild-type MLL, as they have a reduced cellular level of 
MLL, and wild-type MLL is a potential target for leukemia therapy (Thiel et al., 2010). 
This is consistent with our findings, as ASB2 expression in MLL-AF9 transformed 
cells phenocopies knockdown or excision of wild-type MLL, including decreased 
H3K4 methylation, decreased HoxA9 expression and reduced cell proliferation and 
colony formation (Figure 2.18). Notably, ASB2 expression is rapidly induced by 
ATRA (Guibal et al., 2002; Kohroki et al., 2001). This suggests that ATRA treatment, 
which is already in use for treatment of promyelocytic leukemia, would have activity 
against MLL associated leukemias. Indeed, two leukemia cell lines harboring the 
MLL-AF9 fusion protein, THP-1 and MOLM-14 cells, have been shown to be sensitive 




In summary, our work has established a novel ubiquitination pathway for MLL 
degradation during hematopoietic differentiation by ECS
ASB2
. This represents a 
mechanism for HOX gene down-regulation during blood cell maturation by 
degradation of MLL and provides a rationale for targeting the wild-type MLL protein 




Chapter3 A Subset of Mixed Lineage Leukemia Proteins Has PHD 




3.1  Abstract 
The mixed lineage leukemia protein MLL1 (MLL) contains four highly conserved 
plant homeodomain (PHD) fingers, which are invariably deleted in oncogenic MLL1 
fusion proteins in human leukemia. Here we show that the second PHD finger (PHD2) 
of MLL1 is an E3 ubiquitin ligase in the presence of the E2 conjugating enzyme 
CDC34. This activity is conserved in the second PHD finger of MLL4, the closest 
homolog to MLL1 but not in MLL2 or MLL3. Mutation of PHD2 leads to MLL1 
stabilization, as well as increased transactivation ability and MLL1 recruitment to the 
target gene loci, suggesting that PHD2 negatively regulates MLL1 activity 
 
3.2  Introduction 
                                                 
2 This work has been published as Wang, J., Muntean, A.G., Wu, L., and Hess, J.L. (2012). A subset of mixed 
lineage leukemia proteins has PHD domain-mediated E3 ligase activity. J Biol Chem. 




The Mixed Lineage Leukemia protein MLL1 is a histone H3 lysine 4 (H3K4) 
methyltransferase that positively regulates gene expression and plays a key role in 
embryonic development and normal hematopoiesis (Hess et al., 1997). Chromosomal 
translocations involving MLL1 are associated with a variety of hematological 
malignancies, accounting for up to 80% of infant leukemia and approximately 5%-10% 
of adult leukemia overall (Aplan, 2006; Hess, 2004a). In most chromosomal 
translocations, the N terminus of MLL1 is fused to the C terminus of a fusion partner, 
thus forming a chimeric fusion protein with abnormal transactivation ability (Hess, 
2004a). MLL1 contains multiple domains including a region of four PHD fingers on its 
N terminus. Notably, the breakpoint cluster region within MLL1 occurs before or 
within the first PHD finger such that the PHD fingers are invariably lost in the resulting 
MLL1 fusion proteins. Insertion of the PHD fingers into MLL1 fusion proteins 
abolishes their transformation ability (Chen et al., 2008; Muntean et al., 2008).  
In humans, the MLL protein family contains five members (MLL1 (MLL), MLL2 (chr. 
12q13.12, previously referred to as MLL4), MLL3, MLL4 (chr. 19q13.1, previously 
referred to as MLL2), and MLL5). MLL1 through MLL4 are homologous to yeast 
methyltransferase Set1 (MLL5 is considered to be the homolog of the yeast protein 
Set3/Set4) and share greater structural similarity, including multiple PHD fingers on 
their N terminus. Although all the MLL family members have histone 




processes (Lee et al., 2009; Mohan et al., 2011; Shilatifard, 2012; Smith et al., 2011; 
Takahashi et al., 2011). Further, mutations and rearrangements of other MLL family 
member proteins have also been associated with malignancies and other disorders 
(Huntsman et al., 1999; Ng et al., 2010; Ruault et al., 2002; Saigo et al., 2008). Despite 
their biomedical importance, the mechanisms by which these proteins regulate 
transcription and their pathogenesis are not fully understood.  
PHD fingers are zinc-binding motifs that exist in a wide range of proteins. Typical PHD 
fingers contain a Cys4-His-Cys3 consensus that coordinates two Zn
2+
 ions in a 
cross-brace topology (Bienz, 2006). The function of PHD fingers has been under 
intensive study due to their close association with various diseases. These studies have 
revealed that this domain has multiple functions, including recognition of different 
histone marks, DNA binding and mediating protein-protein interactions (Baker et al., 
2008; Li and Li, 2012). Recent studies also discovered that PHD fingers are involved in 
ubiquitination, a post-translational modification implicated in proteasomal degradation 
as well as epigenetic regulation of transcription. Several PHD fingers have been found 
to have E3 ligase activity, including the viral proteins MIR1 and MIR2, as well as the 
eukaryotic proteins Msc1, MEKK1 and AIRE (Coscoy et al., 2001; Dul and Walworth, 
2007; Lu et al., 2002; Uchida et al., 2004). Further, the PHD finger of KAP1 has been 
shown to have SUMO ligase activity, which mediates sumoylation, a process similar to 




In this study, we discovered that the second PHD finger of MLL1 has intrinsic E3 ligase 
activity that is conserved in at least one other closely related MLL family member, 
MLL4. This activity requires the E2 conjugating enzyme CDC34, which interacts with 
MLL1 in vitro and in vivo. Mutation of PHD2 in MLL1 is associated with increased 
transactivation ability and MLL1 recruitment to target gene promoters. 
 
3.3  Experimental Procedures 
3.3.1 Protein purification 
cDNAs encoding the MLL PHD fingers were synthesized (GenScript) and cloned into 
the pMCSG9 vector which contains HIS-MBP tag. Expression plasmids were 
transformed into the AI bacteria strain and screened at the University of Michigan 
High-Throughput Protein Lab. Bacteria were grown at 37℃ in TB medium at 250 
rpms with 50ug/ml spectinomycin and 100ug/ml ampicillin to an OD600 of 
approximately 0.7, and protein expression was induced with 200μM IPT  overnight at 
20℃. Bacteria were lysed by sonication in sodium phosphate buffer (300 mM NaCl, 50 
mM sodium phosphate buffer, 10 mM imidazole, pH 8.0, supplemented with 0.4 mg/ml 
lysozyme). Proteins were batch purified using Ni-NTA agarose (Qiagen) according to 
the manufacturer's instructions and visualized by Coomassie staining. The sequences of 




Protein PHD finger Position (Starting-ending amino 
acid) 
MLL1 PHD1 I1393-F1481 
 PHD2 K1480-G1544 
 PHD3 H1551-P1629 
 PHD4 D1914-L1980 
MLL2 PHD1 E225-R280 
 PHD2 E272-S330 
 PHD3 T1359-S1437 
 PHD4 G1421-S1484 
 PHD5 A1502-V1560 
 PHD6 T5090-G5140 
MLL3 PHD5 S990-S1064 
MLL4 PHD6 Q1239-N1313 
 
3.3.2 In vitro ubiquitination assay 
Purified HIS-MBP tagged PHD fingers (2ug) were incubated with 180ng UBE1 (E1), 
560ng E2, 1ug HA-ubiquitin and 2mM ATP in 30ul reaction buffer (50mM Tris-HCl 
pH7.5, 5mM MgCl2, 2mM NaF, 0.5mM DTT) at room temperature for 3 hours. 
Reactions were terminated by adding 30ul 2X SDS sample buffer (Invitrogen) and 
boiling at 95℃ for 5-10min. Western blotting was then performed to detect ubiquitin 
conjugates using HA antibody (Abcam). For the ubiquitination assays using histones as 
substrates, 1ug of recombinant histone H2A, H2B, H3 or H4 (Boston Biochem) were 
added to the reactions respectively. Human recombinant UBE1, CDC34, RAD6, 
UBCH5c, and HA tagged ubiquitin were purchased from Boston Biochem. Human 





3.3.3 In vitro binding assay 
Equal amounts of purified HIS-MBP/ HIS-MBP–PHD2 and recombinant CDC34 (1ug) 
were incubated in 500ul binding buffer (50mM Tris-HCl pH7.9, 300mM KCl, 0.05% 
NP40, 0.1% BSA) for 2 hours at 4℃. 20ul Amylose resin (New England Biolabs) was 
then added to the reaction and incubated for 1 hour at 4℃. Bound material was washed 
with wash buffer (50mM Tris-HCl pH 7.9, 300 mM KCl, 0.3% NP40) 3 times and 
eluted from beads by boiling in SDS sample buffer. Eluted material was detected by 
western blotting and Coomassie staining. 
3.3.4 Immunoprecipitation and Western blotting 
Immunoprecipitation and western blotting were performed as previously described 
(Chen et al., 2008). 293 cells were lysed with BC-300 lysis buffer (20mM Tris-HCl [pH 
7.4], 10% glycerol, 300mM KCl, 0.1% NP-40) and incubated with protein-G agarose 
beads (Roche) and MLL1 antibody or normal IgG overnight at 4℃. Bound material 
was washed 3 times with BC-300 buffer. Proteins were eluted by boiling in SDS 
loading buffer, resolved by SDS-PAGE, and detected by western blotting. Primary 
antibodies against MLL1 and CDC34 were obtained from Bethyl and Upstate, and 
Boston Biochem respectively.  
3.3.5 Vector construction and Dual Luciferase Assay 
pCXN2-Flag-MLL1 have been previously described (Milne et al., 2002). 




pCXN2-Flag-MLL1 using the QuikChange Site-Directed Mutagenesis Kit (Agilent). 
293 cells were transfected with MLL1 or MLL1 mutants, Renilla luciferase reporter 
(serves as an internal control), and Hoxa9-LUC or Myc-LUC reporter with FuGene 6 
according to the manufacturer's instructions. The amount of MLL1 and MLL1 mutant 
constructs transfected was adjusted to yield equal protein levels (MLL1: 
MLL1C1509A: MLL1ΔP2 =1:1.2:1). Vector DNA was added to ensure that the total 
amount of DNA transfected was equal among all samples. Cells were serum starved in 
0.5% FBS in OPTI-MEM media for 48 hours. Luciferase assays were performed using 
the Dual Luciferase Assay Kit (Promega) according to the manufacturer's instructions. 
Emission was detected using a Monolight 3010 Luminometer (BD Biosciences). 
3.3.6 Chromatin immunoprecipitation (ChIP) 
ChIP assays were performed as previously described (Milne et al., 2005). Antibody 
against Flag tag was obtained from Sigma-Aldrich. qPCR was performed on the 
precipitated DNAs with TaqMan primers and probes from Applied Biosystems. 
Binding was quantitated as follows: ΔCT = CT(input)−CT(Chromatin IP), % total = 
2
ΔCT
. Primer and probe sequences are described previously (Wang et al., 2011b). 
 
3.4  Results  




The MLL1 protein contains four PHD fingers (PHD1-4) with conserved Zn
2+
 
coordinating cysteine and histidine amino acids and variable intervening sequences 
(Figure 3.1A).  
Figure 3.1. Sequence alignment of the four PHD fingers of MLL1 
 
Figure 3.1. Sequence alignment of the four PHD fingers of MLL1. (A) (Upper) Schematic 
diagram of the structure of wild-type MLL1. (Lower) Sequence alignment of the four PHD 
fingers of MLL1. Black background indicates conserved cysteines and histidines. Grey 
background indicates other conserved amino acids. “*” indicates the cysteine in PHD2 that is 
mutated in this study. 
 ecent publications have shown that PHD fingers can function as an H3K4me3 “reader” 
(Li et al., 2006). While the third PHD finger of MLL1 shares this high affinity 
recognition specifically for H3K4me3, this activity is notably absent from PHD1, 2 and 
4 of MLL1 (Chang et al., 2010b). As several PHD fingers function as E3 ligases, we 
investigated whether any of the MLL1 PHD fingers have this activity. To this end, we 
bacterially expressed and purified HIS-MBP-tagged individual PHD fingers of MLL1 
(Figure 3.2A). In vitro ubiquitination assays were performed in the presence of E1 
activating enzyme UBE1, E2 conjugating enzyme CDC34, HA-tagged Ubiquitin and 




of PHD2 (Figure 3.2B). This activity is ATP-dependent, as no ubiquitination was 
observed without ATP (Figure 3.2B, lane 6). To confirm this enzymatic activity, the 
sixth cysteine of PHD2 was mutated to alanine to disrupt the cross-brace structure of 
the domain. No ubiquitination activity was observed with the mutant, indicating that 
the observed E3 ubiquitin ligase activity is intrinsic to PHD2 (Figure 3.2C).  
Figure 3.2 The second PHD finger of MLL1 has E3 ligase activity in vitro 
 
Figure 3.2. The second PHD finger of M LL1 has E3 ligase activity in vitro. (A) 
Coomassie staining of purified PHD fingers. (B) In vitro ubiquitination assays with the four 
PHD fingers of MLL1 followed by western blotting for HA-tagged ubiquitin shows that the 
second PHD finger promotes formation of poly-ubiquitin conjugates in the presence of ATP. 
Commassie staining indicates equal amount of PHD fingers used in the assay. (C) In vitro 
ubiquitination assays were performed with wild type or mutant PHD2 followed by HA western 




To test if PHD2 can ubiquitinate other substrates, in vitro ubiquitination assays were 
performed with free histones, including H2A, H2B, H3 and H4. PHD2 showed specific 
activity for histone H3 and H4, but not H2A or H2B (Figure 3.3A). To identify the sites 
on histone H3 and H4 that are ubiquitnated, mass spectrometry analysis was performed 
on these histones from the ubiquitination assays. Three sites were identified, including 
H3K79, H3K122 and H4K31.  
Figure 3.3 PHD2 ubiquitinates histones in vitro. 
 
Figure 3.3. PHD2 ubiquitinates histones in vitro. (A) In vitro ubiquitination assays with PHD2 
using histones as substrates. Western blotting shows that PHD2 leads to ubiquitination of 
histone H3 and H4. Commassie staining indicates equal amount of materials used in the assays. 
M = MBP, P2 = PHD2. 
3.4.2 PHD E3 ligase activity is conserved in MLL4 
The MLL protein family consists of five members (MLL1-MLL5), with MLL4 




conserved among the MLL family members, a sequence alignment of all predicted 
PHD fingers in MLL1 through MLL4 was performed, which revealed the highest 
homology between the second PHD finger (PHD2) of MLL4 and PHD2 of MLL1. The 
fourth PHD finger (PHD4) of MLL2 and the fifth PHD finger (PHD5) of MLL3 are the 
next most similar to PHD2 of MLL1 (Figure 3.4A and B). Further, the alignment shows 
that each PHD finger in MLL4 clusters together with the corresponding PHD fingers in 
MLL1, while five of the six PHD fingers in MLL2 cluster together with the 
corresponding PHD fingers in MLL3 (Figure 3.4A). Notably, previous studies have 
shown that MLL1 and MLL4 are functionally distinct from MLL2 and MLL3, which 
form unique macromolecular protein complexes and target distinct genes (Figure 3.4C) 




Figure 3.4 The second PHD finger (PHD2) of MLL4 shows highest similarity to 
PHD2 of MLL1 
 
Figure 3.4. The second PHD finger (PHD2) of MLL4 shows highest similarity to PHD2 of 
MLL1. (A) Phylogenetic tree using Clustal W (Thompson et al., 1994) with neighbor joining 
method based on sequence alignment of the PHD fingers of MLL1 through MLL4. Dashed 
circle indicates the PHD fingers that are similar to PHD2 of MLL1. (B) Sequence alignment of 
PHD4 of MLL2, PHD5 of MLL3 and PHD2 of MLL4 with PHD2 of MLL1 respectively. Black 
background indicates conserved cysteines and histidines. Grey background indicates other 
conserved amino acids. (C) Schematic diagram showing the structure of MLL 
methyltransferase complexes. Black indicates MLL proteins. Dark grey indicates common 
subunits. Light grey indicates unique subunits. Star indicates E3 ligase activity. 
To test for conservation of E3 ligase activity, HIS-MBP-tagged PHD2 of MLL4, PHD5 
of MLL3 and all PHD fingers of MLL2 were bacterially expressed, purified and tested 
in in vitro ubiquitination assays (Figure 3.5A-B). These showed that only the most 




activity was observed in other MLL family member PHD fingers under the same 
conditions (Figure 3.5C-D). These data demonstrate a novel E3 ubiquitin ligase activity 
associated with PHD2 of MLL1 that is evolutionarily conserved in PHD2 of MLL4.  
Figure 3.5 The E3 ligase activity is conserved in PHD2 of MLL4 
 
Figure 3.5. The E3 ligase activity is conserved in PHD2 of MLL4. (A-B) Commassie staining 
of bacteria expressed and purified PHD fingers. (C) In vitro ubiquitination assays with PHD2 of 
MLL1, PHD4 of MLL2, PHD5 of MLL3 and PHD2 of MLL4. Western blotting shows that the 
PHD finger of MLL1 and MLL4 contain ubiquitinating activity. (D) In vitro ubiquitination 
assays with PHD2 of MLL1 and the PHD fingers of MLL2. None of the MLL2 PHD fingers 
show ubiquitinating activity.  




The interaction between E2 conjugating enzymes and E3 ligases plays a central role in 
ubiquitination as it provides specificity to the reaction. We sought to identify the E2 
conjugating enzyme required for PHD2 activity by performing ubiquitination assays 
with a panel of E2 enzymes, including CDC34, RAD6, UBCH5c and UBCH13. 
Ubiquitin conjugates were only observed in the presence of CDC34, demonstrating 
specificity for CDC34 in PHD2-mediated ubiquitination (Figure 3.6A). To test for a 
direct interaction, in vitro binding assays were performed using purified 
HIS-MBP-PHD2 and recombinant CDC34. Immunoprecipitation of PHD2 but not the 
tag control leads to co-precipitation of CDC34 (Figure 3.6B). We then tested for an 
endogenous interaction between full length MLL1 and CDC34 in 293 cells. 
Endogenous MLL1 was immunoprecipitated using anti-MLL1 antibody and western 
blotting using anti-CDC34 antibody showed that endogenous CDC34 co-precipitates 




Figure 3.6 CDC34 facilitates the E3 ligase activity of PHD2 and interacts with MLL1 
 
Figure 3.6. CDC34 facilitates the E3 ligase activity of PHD2 and interacts with MLL1. 
(A) In vitro ubiquitination assays of PHD2 with different E2 enzymes showing a specific 
requirement for CDC34. Commassie staining indicates the amount of E2 enzymes for each 
assay. The two bands in lane 6 represent UBCH13 (lower) and Uev2a (upper). (B) In vitro 
binding assays with purified PHD2 and recombinant CDC34 indicates that CDC34 
co-precipitates with PHD2 but not the HIS-MBP tag control. (C) Immunoprecipitation of 
endogenous MLL1 co-precipitates endogenous CDC34. 
3.4.4 Transcriptional activity of MLL1 is augmented by mutation of PHD2 
MLL1 is a positive regulator of gene expression. To test the effect of PHD2 on MLL1 
transactivation ability, two mutants were made in the context of full length MLL1. 
MLL1C1509A replaces the sixth cysteine of PHD2 with alanine, which resembles the 




length MLL1 with a deletion of the entire PHD2. Wild type MLL1 or MLL1 mutants 
were expressed in 293 cells with a luciferase reporter driven by the promoter of Hoxa9 
(Hoxa9-LUC), an important target gene of MLL. Dual Luciferase Assays were 
performed to test the activation of the reporter, which reflects the transactivation ability 
of MLL1 (Figure 3.7A). Both MLL1C1509A and MLL1ΔP2 showed higher 
transactivation compared to wild type MLL1 (Figure 3.7B and C). Similar results were 
observed when using a luciferase reporter driven by the Myc promoter, another target of 
MLL1 (Figure 3.7D).  
Figure 3.7 Mutation of PHD2 in MLL1 leads to increased MLL1 transactivation 
ability 
 
Figure 3.7. Mutation of PHD2 in MLL1 leads to increased MLL1 transactivation ability. (A) 
Schematic diagram of the Hoxa9-LUC reporter. Black bars indicate the position of the probes 




in 293 cells. β-ACTIN blot shows equal loading. (C) Dual Luciferase Assays were 
performed in 293 cells with Hoxa9-LUC reporter showing that mutations of PHD2 in full 
length MLL1 lead to higher activation of Hoxa9 reporter compared to wild type MLL1. All 
changes are normalized to lane 1, which contains Hoxa9-LUC and an empty expression vector. 
Error bars indicate SD. (D) Dual luciferase assay was performed in 293 cells with 
Myc-LUC reporter. 
Further, chromatin immunoprecipitation (ChIP)–qPCR experiments were performed to 
test the recruitment of MLL1 or MLL1 mutants to the promoter region of the Hoxa9 
reporter. 293 cells were transfected with MLL1 or MLL1 mutant expression vectors 
and Hoxa9-LUC reporter at the same ratio as used in the Dual Luciferase Assays. This 
yielded comparable levels of MLL1 and MLL1 mutant expression (data not shown). 
ChIP-qPCR revealed a more robust recruitment of both MLL1 mutants compared to 




Figure 3.8 Mutation of PHD2 in MLL1 leads to increased MLL1 recruitment to 
target gene loci 
 
Figure 3.8. Mutation of PHD2 in MLL1 leads to increased MLL1 recruitment to target gene 
loci. (A) ChIP-qPCR assays were performed in 293 cells transfected with Hoxa9-LUC, MLL1 
or MLL1 mutants. X axis labels the distance of the probes relative to the transcription start site. 
Grey line: vector control. Solid line with squares: wild-type MLL1. Long dashed line with 
triangles: MLL1C1509A. Short dashed line with crossings: MLL1ΔP2. 
To test the effect of PHD2 on MLL1 stability, the turnover of MLL1 and 
MLL1C1509A was monitored following treatment with cycloheximide. In these 
experiments, MLL1C1509A displayed prolonged degradation and greater stability than 




Figure 3.9 Mutation of PHD2 in MLL1 leads to increased MLL1 stability 
 
Figure 3.9. Mutation of PHD2 in MLL1 leads to increased MLL1 stability. (A) 293 cells 
transfected with MLL1 or MLL1C1509A were treated with cycloheximide for different time 
periods as indicated to block translation. The turnover of MLL1 or MLL1C1509A was 
monitored by western blotting using whole cell lysate. MLL1C1509A shows prolonged protein 
degradation compared to wild type MLL1. 
 
3.5  Discussion 
MLL1 contains four PHD fingers, which are invariably deleted in leukemogenic MLL1 
fusion proteins. Moreover, insertion of the PHD fingers into MLL1 fusion proteins 
abolishes their transformation ability (Chen et al., 2008; Muntean et al., 2008). 
Sequence variation between the MLL1 PHD fingers suggests that they have different 
functions. Indeed, the third PHD finger of MLL1 has been reported to bind 
di/tri-methylated histone H3K4 and the cyclophilin Cyp33 simultaneously while the 
first and fourth PHD fingers are involved in mediating intramolecular interactions 




et al., 2010; Yokoyama et al., 2011). Here we report that MLL1 contains a second 
enzymatic activity in addition to the methyltransferase activity intrinsic to the SET 
domain. The second PHD finger functions as an E3 ligase in conjugation with the E2 
enzyme CDC34. Mutation of PHD2 leads to increased transactivation ability of MLL1 
and its recruitment to target genes, which is likely due to increased protein stability 
(Figure 3.8-3.9). However, PHD2 may also ubiquitinate other substrates that contribute 
to its inhibitory effect. Interestingly, we observed that PHD2 ubiquitinates histone H3 
and H4 in vitro, and three ubiquitination sites were identified, including H3K79, 
H3K122 and H4K31. Notably, all these sites have been found to be ubiquitinated in 
vivo (Kim et al., 2011; Wagner et al., 2011), while the E3 ligases that mediate these 
modifications and their biological functions remain to be determined. Further, a 
sequence analysis was reported that characterizes the surrounding sequences of each 
lysine residue in human histones H2A, H2B, H3 and H4. In this analysis, clustering was 
performed with each lysine and its twelve flanking residues. H3K79, H3K122 and 
H4K31 cluster together (Basu et al., 2009), indicating that these sites share sequence 
similarities that are preferentially recognized and ubiquitinated by PHD2. Further 
experiments are required to determine if histone H3 and H4 are bona fide substrates in 







(Liu et al., 2007a; Wang et al., 2011b). Our findings indicate 




important regulator of cell cycle progression (King et al., 1996), raising the possibility 
that PHD2 plays a role in regulating MLL1 degradation during cell cycle.  
The MLL protein family contains five members, with MLL1 and MLL4 being 
functionally distinct from MLL2 and MLL3 (Lee et al., 2009; Mohan et al., 2011; 
Shilatifard, 2012; Smith et al., 2011; Takahashi et al., 2011). This is reflected from the 
sequence alignment of the MLL PHD fingers, as the PHD fingers of MLL1 and MLL4 
cluster together while the PHD fingers of MLL2 and MLL3 cluster together (Figure 3.4 
A). Further, the PHD2 of MLL4 also has E3 ligase activity (Figure 3.5). Like MLL1, 
MLL4 also undergoes cancer associated gene rearrangements. In one study, intronic 
insertions of hepatitis B virus (HBV) genomic sequences or chromosomal 
translocations of MLL4 were found in 26 out of 42 human hepatocellular carcinoma 
(HCC) cases suggesting MLL4 overexpression or alteration plays a key role to the 
pathogenesis of HCC (Saigo et al., 2008). Given the central role of MLL family 
members and their frequent rearrangements and mutations in both leukemia and solid 
tumors, additional studies appear warranted to define the role of PHD finger mediated 





Chapter4 The Functional Interactions between HOXA9, C/EBPΑ and PU.1 
4.1  Abstract 
HOXA9 is a homedomain-containing transcription factor that plays a crucial rule in 
embryonic development and normal hematopoiesis. Constitutive activation of HOXA9 
is associated with a variety of hematopoietic malignancies, including MLL fusion 
mediated leukemia, and plays a key role in their pathogenesis. Using motif analysis of 
genome-wide HOXA9 binding and mass spectrometry, we previously found that 
C/EBPΑ and PU.1 are potential HOXA9 cofactors. In this study, we characterized the 
co-binding between Hoxa9, C/ebpα and Pu.1 on the genome and its association with 
Hoxa9 regulated gene expression using next-generation DNA sequencing coupled 
with chromatin immunoprecipitation (ChIP-seq) and whole transcriptome sequencing 
(RNA-seq). Different ChIP-seq and RNA-seq analysis methods were tested and 
compared to optimize the analysis pipeline. Based on these data, we found that 
genome-wide Hoxa9 binding overlaps with C/ebpα and Pu.1 binding. Co-bound 
regions are enriched with the enhancer mark H3K4me1, and are enriched for 
hematopoiesis related pathways. Further, co-binding of C/ebpα and Pu.1 associates 





4.2  Introduction 
HOXA9 is a member of the HOX transcription factor family and is one of the 
best-studied MLL target genes. It maintains the self-renewal ability of hematopoietic 
stem cells and progenitors and functions as a master regulator of hematopoiesis 
(Argiropoulos and Humphries, 2007). Constitutive activation of Hoxa9 is associated 
with a variety of hematopoietic malignancies, including MLL translocation-mediated 
leukemia, NPM1 mutation associated AML and CDX2/CDX4 mediated leukemia, 
and plays a key role in their pathogenesis (Bansal et al., 2006; Mullighan et al., 2007; 
Rawat et al., 2008). In fact, HOXA9 up-regulation is present in approximately 50% of 
all AML cases and it was identified as the most highly correlated gene for poor 
prognosis in AML (Golub et al., 1999; Lawrence et al., 1999). Further, 
HOXA9-NUP98 fusion resulting from chromosome translocation leads to aberrant 
gene expression profiling and is associated with AML, trilineage MDS and chronic 
myelomonocytic leukemia (Borrow et al., 1996; Hatano et al., 1999; Inaba et al., 1996; 
Kroon et al., 2001; Nakamura et al., 1996; Wong et al., 1999). 
Although being established for a long time as the key regulator of hematopoiesis and 
important mediator of leukemia, the mechanisms of HOXA9 regulated gene 
expression remains poorly understood. Specifically, how does HOXA9 recognize its 
target genes, and how is the gene activation or repression activity determined? To 




transcription factors and chromatin modifiers (HOXA9 cofactors) form a complex 
with HOXA9 and bind to DNA in a cooperative pattern, thus increasing the binding 
specificity, affinity or transactivation ability of HOXA9 (Mann et al., 2009). One 
example of HOXA9 cofactor is the non-Hox homeodomain protein MEIS1. MEIS1 
can dimerize with HOXA9, or form a triple complex with HOXA9 and PBX proteins 
(PBX1-3), another class of HOXA9 cofactors that contain a homeodomain with ~40% 
identity to that of MEIS1. These interactions stabilize the HOXA9 DNA binding 
complex. Also, addition of MEIS1 binding consensus (TGACAG) and PBX binding 
consensus (TGAT) increases the specificity of HOXA9 recognition on target loci 
(Shen et al., 1997; Shen et al., 1999).  
To better understand the mechanisms of HOXA9 regulated gene expression and to 
discover other HOXA9 cofactors, the Hess lab performed ChIP-seq experiment to 
define the genome-wide binding pattern of Hoxa9 using a murine cell line 
transformed with Hoxa9 and Meis1. This identified ~400 binding peaks for Hoxa9 
with more than 50% of them overlapping with Meis1 binding, consistent with the role 
of Meis1 as Hoxa9 cofactor. Hoxa9 binding sites show high levels of histone 
H3K4me1 and CBP/P300 binding characteristic of enhancers, suggesting a role of 
Hoxa9 on the enhancer elements. Interestingly, de novo motif analysis reveals that 
Hoxa9 peaks are enriched with binding motifs of several transcription factors and 
chromatin modifiers, such as PU.1, C/EBP, RUNX1 and STAT5 (Huang et al., 2012). 




Hoxa9, which was also confirmed by in vitro binding assays and/or 
co-immunoprecipitation. These findings support that these proteins are potential 
HOXA9 cofactors.  
In this study, we focus on the functional interaction between HOXA9, the 
CCAAT/enhancer-binding protein alpha (C/EBPA) and the ETS transcription factor 
PU.1 (also called SPI1). C/EBPA and PU.1 are both key regulators of hematopoiesis, 
especially myeloid lineage development. PU.1 is expressed in lymphoid-myeloid 
progenitor (LMP) cells and their progeny cells, and is required for the generation of 
both common lymphoid progenitor (CLP) and granulocyte-macrophage progenitor 
(GMP) cells. Knockout of Pu.1 in mice leads to significant decrease of CLP and GMP 
populations, thus absence of B cells and monocytes and greatly reduced neutrophils 
(Friedman, 2007; Iwasaki et al., 2005). C/EBPA is expressed in HSC, common 
myeloid progenitor (CMP) and GMP cells. C/ebp  knockout in mice blocks the 
transition from CMP to GMP cells. Consistent with this, these mice lack neutrophils 
and eosinophils and have reduced monocytes in their fetal and newborn livers 
(Friedman, 2007; Zhang et al., 2004). 
4.3  Experimental Procedures 
4.3.1 Cell culture (Performed by Cailin Collins) 
Hoxa9, Meis1 transformed murine cell line was established as described in (Huang et 




5-fluorouracil–treated female 6- to 8-week-old C57BL/6 mice and transformed into 
myeloblastic cell lines with a murine stem cell virus –based retrovirus expressing 
HA-tagged Hoxa9 fused to a modified estrogen receptor ligand-binding domain 
(Hoxa9-ER) and Meis1. Cells were cultured in IMDM with 15% FBS (StemCell 
Technologies) with penicillin/streptomycin, IL-3 (10ng/ml, R&D Systems) and 
4-hydroxytamoxifen (4-OHT; 100nM, Sigma-Aldrich). Double Hoxa9/Meis1 
transductants were selected by FACS (bicistronic Meis1+GFP expression using MigR1 
vector; a gift from Dr Warren S. Pear, University of Pennsylvania). 
4.3.2 ChIP-sequencing (Performed by Cailin Collins) 
Chromatin Immunoprecipitation (ChIP) was performed as described previously 
(Huang et al., 2012). Thirty million cells were used per IP and the following antibodies 
are used: HA (Abcam, Ab9110), C/ebpα (Santa Cruz, 14AA SC-61), Pu.1 (Santa Cruz, 
sc352 T21), H3K4me1 (Abcam, ab8895), H3K27me3 (Millipore, 07-449). For 
ChIP-seq analysis, 10 ng of ChIPed DNA was processed for library generation using 
the ChIP-seq Library Preparation Kit (Illumina) following the manufacturer’s protocol. 
The sequencing was performed on Illumina™ HiSeq2000 at University of Michigan 
DNA sequencing core and raw ChIP-seq data were processed using the Illumina 
software pipeline.  




For RNA sequencing, one million cells in culture with 4-OHT or at 72hrs upon 
withdrawal of 4-OHT were used per sample. RNA was extracted using Qiagen RNeasy 
kit following the manufacturer’s protocol. Sequencing was performed on Illumina™ 
HiSeq2000 at University of Michigan DNA sequencing core and raw RNA-seq data 
were processed using the Illumina software pipeline. 
4.3.4 Peak Calling 
Sequenced reads were pre-processed to remove contamination of adaptor sequences 
and then aligned to mouse reference genome (mm9) using BWA (version 0.6.2) (Li and 
Durbin, 2009). Three peak calling programs were tested and compared, including 
Model-based Analysis for ChIP-Seq (MACS) (Zhang et al., 2008), CisGenome (Ji et al., 
2008) and ChIPseeqer (Giannopoulou and Elemento, 2011). The parameters used are as 
below (default values are used if not specified): 
MACS: format=BED -g mm --nomodel --shiftsize 75 -w –S 
ChIPseeqer : -t 15 -fold_t 2 -readlen 52 -fraglen 150 
CisGenome: default parameters are used 
Distribution of peaks in the promoter (-1kb to +100bp of TSS), exon, intron, and 
intergenic regions (outside of the defined regions above) was estimated using HOMER 





Histograms for the distance between Hoxa9 peaks and the transcription start site (TSS) 
of their nearest gene are plotted using R program with bin width set to 
max(X)-min(X))/(1+log2(length(X)) according to the Sturges' bin rule. Densities of the 
peak-TSS distance for Hoxa9, C/ebpα and Pu.1 were estimated using Kernel Density 
Estimation using Gaussian distribution as the kernel.  
 
4.3.5 Functional and statistical analysis of ChIP-seq data 
Peak overlap was performed using HOMER with the criteria that there is at least 1 
basepair overlap between tested peaks (Heinz et al., 2010). The overlap was also 
confirmed using the R package ChIPpeakAnno, which generated similar results. The 
significance of peak overlap was calculated using hypergeometric test from the R 
package ChIPpeakAnno. The background (total number of tests) was set to 159,029 as 
an estimation of total transcription factor binding sites obtained from K526 leukemia 
cells (Yip et al., 2012). A smaller background of 100,189 was also used, which is the 
peak number of H3K4me1, representing the total number of enhancer elements 
specifically in our murine cell line. This is a more conservative background as the three 
proteins can also bind to non-enhancer regions. Both backgrounds generated consistent 
results. The p-values from the former one are presented in the text.  
Quantification of histone mark binding signals was calculated using HOMER. 




normalized to 10 million and then normalized that the resulting units are per bp per 
peak. Heatmap was made with Cluster 3 (de Hoon et al., 2004), and visualized using 
Treeview (Page, 1996). Histone mark distributions are plotted in excel (Heinz et al., 
2010).   
De novo motif analysis was performed using MEME-ChIP (Machanick and Bailey, 
2011). Hoxa9 binding regions were trimmed to a centered peak core sequence of 200 bp 
for analysis. A motif is considered to be statistically significantly enriched if the 
number of sequences in which the motif is found to be present is significantly higher 
than its expected whole-genome occurrences according to E score (comparable to 
p-value) <0.05 generated by the MEME and DREME algorithms. The de novo motif 
discovery module of HOMER and ChIPseeqer were also used which generated similar 
results to MEME-ChIP. Comprehensive search of known motifs was performed against 
865 transcription factor motifs included in Genomatix proprietary Mat Base Matrix 
Family Library (Version 8.2, January 2010). A motif is considered to be statistically 
significantly enriched according to standard z-test (z-score >2.81; p-value < 0.005), 
using the whole genome as background.  
Pathway analysis was performed using GREAT software based on Binomial test 
p-value <0.05 (McLean et al., 2010). Other analysis was performed using R 
programming. 




Sequenced reads were aligned to mouse reference genome (mm9) using Bowtie and 
Tophat (version 2.0.3) (Kim et al., 2013). Two programs were tested and compared for 
differential expression analysis, Cuffdiff (Trapnell et al., 2010) and EdgeR (Robinson 
et al., 2010), which generated similar results. Pathway analysis was performed using 
Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005).  
4.3.7 Incorporation of ChIP-seq and RNA-seq data  
Incorporation of ChIP-seq and RNA-seq data was performed using R programming. 
Genes are divided into classes according to binding patterns of Hoxa9, C/ebpα and Pu.1, 
and their expression levels are extracted from RNA-seq data.  
To compare the percentages of genes with significant expression change between 
classes of genes with different binding patterns, and the percentages of down- (up-) 
regulated genes in genes, Fisher Exact test was performed for pairwise comparison, and 
Chi square test was performed for multiple group comparison. P-value <=0.05 is 
considered to be statistically significant.  
To compare the magnitude of gene expression change, fold change for each gene was 
transformed by log2. Nonparametric Wilcoxon Rank Sum test was performed for 
pairwise comparison and Kruskal-Wallis test was performed for multiple group 
comparison. P-value <=0.05 is considered to be statistically significant. Parametric 




group comparison, respectively, which generate consistent results with nonparametric 
tests. 
4.4  Results  
4.4.1 Characterization of genome-wide binding of Hoxa9, C/ebpα and Pu.1 
To study the genome-wide binding patterns of Hoxa9, C/ebpα and Pu.1, we used a 
murine cell line in which bone marrow cells were transduced with HA-tagged Hoxa9 
fused to a modified estrogen receptor ligand-binding domain (HA-Hoxa9-ER) and Flag 
tagged Meis1 expression vectors, and maintained in the presence of 
4-hydroxytamoxifen (4-OHT). The presence of HA tag enables efficient 
immunoprecipitation of Hoxa9, as we were not able to obtain a ChIP-seq qualified 
antibody against endogenous Hoxa9 (Muntean et al., 2010). Western blotting showed 
that the expression levels of Hoxa9 and Meis1 in these cells were comparable to 
MLL-AF9 leukemia cells (Huang et al., 2012). Illumina based ChIP-sequencing 
libraries were prepared using antibodies against HA, C/ebpα and Pu.1. As previous 
ChIP-on-chip experiments show that factors associated with enhancers are present on 
Hoxa9 binding regions, such as p300, CBP and H3K4me1, we also included antibodies 
against enhancer associated histone marks, including H3K4me1, which marks general 
enhancers, H3K27ac, which marks active enhancers, and H3K27me3, which marks 
poised enhancers (Rada-Iglesias et al., 2011). Unfortunately, the H3K27ace ChIP-seq 




ChIP-seq samples were sequenced on Illumina™ HiSeq2000 system. Sequenced reads 
were then aligned to the mouse mm9 reference genome. Overall, for each sample we 
obtained more than 20 million reads aligned to the reference genome (Table 4.1).  
Table 4-1 Summary of the number of sequenced and aligned reads 
Sample Total No. of 
sequences 




Input 54,768,760 40,932,499 74.7% 
HA (Hoxa9) 43,378,206 33,630,123 77.5% 
C/ebpα 40,609,786 29,679,136 73.1% 
Pu.1 34,363,360 23,702,997 69% 
H3K27me3 55,631,183 40,191,253 72.2% 
H3K4me1 38,787,174 20,961,523 54% 
 
Three peak calling programs were tested for their performance using Hoxa9 ChIP-seq 
data, including Model-based Analysis for ChIP-Seq (MACS) (Zhang et al., 2008), 
CisGenome (Ji et al., 2008) and ChIPseeqer (Giannopoulou and Elemento, 2011). 
Overall, MACS detected the largest number of peaks, consistent with previous reports 
that MACS has high sensitivity, while ChIPseeqer detected the smallest number of 
peaks (Figure 4.1B). However, results from the three programs showed significant 
overlap (hypergeometric test p-values =0 for pairwise comparisons of MACS vs. 
CisGenome, CisGenome vs ChIPseeqer, and MACS vs. ChIPseeqer), with 653 peaks 
detected by all three, representing 75% of ChIPseeqer detected peaks, 18% of 




Results of the three peak calling programs were further evaluated based on seven gene 
loci that we previously discovered and confirmed using ChIP-qPCR for Hoxa9 binding, 
including two sites with high level binding (>30), three sites with medium level binding 
(10 < IP signal/IgG signal < 30) and two sites with low level binding (5 < IP signal/IgG 
< 10) (Figure 4.1A). All of the three programs detected the two sites with high Hoxa9 
binding. However, only MACS was able to detect the three sites with medium level 
binding, while CisGenome and ChIPseeqer missed one and two sites, respectively. 
None of the programs was able to detect the two sites with low Hoxa9 binding, 
supporting the stringent setting of their parameters to reduce false positive detection 
(Figure 4.1A, C). So we decided that MACS best captures Hoxa9 binding signal, and 
this program was used for later analysis. Default p-value cutoff of 1e-5 was used, as a 
more stringent cutoff (1e-6) failed to detect all the median level sites (Figure 4.1C 
column 5 and 6). Further, detected peaks also significantly overlap with previous report 




Figure 4.1 Comparison of three peak calling programs, MACS, CisGenome and 
ChIPseeqer 
 
Figure 4.1. Comparison of three peak calling programs, MACS, CisGenome and ChIPseeqer. 
(A) ChIP-qPCR of seven gene loci with different levels of Hoxa9 binding. (B) Venn Diagram 
showing the overlap of peaks detected by the three programs. (C) Summary of the Hoxa9 
binding levels of the seven gene loci and whether they are detected by each peak calling 
program. For MACS, two p-value cutoffs were tested. p-value =1e-5 is the default setting of 
this program. 
Overall, 6578 Hoxa9 binding peaks, 19093 Pu.1 binding peaks, 26446 C/ebpα binding 
peaks, 100189 H3K4me1 binding peaks and 33769 H3K27me3 binding peaks were 
detected with false discovery rate (FDR) < 0.05 (Figure 4.2). The peaks were then 
annotated with information on genomic regions including promoter (defined as -1kb to 




~48% of the peaks reside in intergenic regions; ~46% reside in intronic regions; while 
only ~2% of the peaks reside in promoter regions. This distribution is similar to 
previous report, and the lower percentage of promoter associated peaks is due to a more 
stringent definition of promoters (compared to promoter defined as -2kb to +1kp of 
TSS in (Huang et al., 2012)) (Figure 4.2A). The Hoxa9 peaks were then annotated to 
the nearest gene, and the distance between each peak and the gene transcription start 
site (TSS) was calculated and plotted (Figure 4.2B, histogram and blue line). The 
average distance is ~40kb, and ~80% of the peaks reside in between 5kb and 250kb 
regions from the TSS. Pu.1 and C/ebpα also have majority of their peaks residing in 
intergenic and intronic regions, although these two proteins have a higher percentage of 
promoter associated peaks (Figure 4.2A). The distribution of the peak-TSS distance for 








Figure 4.2. (A) Summary of Hoxa9, C/ebpα, Pu.1, H3K4me3 and H3K27me3 binding peaks, 
including total number of peaks (column2), false discovery rate (FDR) (column 3) and 
distribution of the peaks (column4). Red indicates intronic regions. Blue indicates intergenic 




of the distance between Hoxa9, C/ebpα and Pu.1 peaks to the transcription start site of the 
nearest genes. Histogram of Hoxa9 peak distribution was plotted. Lines indicate estimated 
densities of peak-TSS distance for Hoxa9 (blue), C/ebpα (red) and Pu.1 (green). X axis labels 
the log10 transformation of the distance to TSS in basepair. Y axis labels the density of the 
distribution.  
To characterize the distribution of histone marks around Hoxa9 binding sites, heatmap 
was generated displaying the binding signals of H3K4me1 and H3K27me3 -3kb to 
+3kb from the center of each Hoxa9 peak. Hoxa9 binding regions are largely enriched 
with the enhancer mark H3K4me1. Importantly, H3K27me3, which generally marks 
poised enhancers and are associated with inactive gene expression, was depleted from 
Hoxa9 binding regions. This data together with the distribution of Hoxa9 peaks in 
intergenic and intronic regions support an active role of Hoxa9 on the enhancer 
elements(Figure 4.3).  
Figure 4.3 Distribution of histone marks around Hoxa9 binding peaks 
 
Figure 4.3. Distribution of histone marks around Hoxa9 binding peaks. (A) Heatmap showing 




binding peaks. Each row indicates a Hoxa9 peak, ranked from high to low according to average 
Hoxa9 density.  
4.4.2 Hoxa9 co-localizes with C/ebpα and Pu.1 on the genome 
The similar distribution of Hoxa9, C/ebpα and Pu.1 binding peaks (Figure 4.2) 
indicates that the three proteins may co-localize on the genome. To test this, we 
calculated the overlap between Hoxa9, C/ebpα and Pu.1 binding peaks. Among the 
6578 Hoxa9 binding peaks, 3584 (~54%) overlap with C/ebpα binding peaks 
(Hypergeometric test p-value=0), 1851 (28%) overlap with Pu.1 binding peaks 
(Hypergeometric test p-value=1.917467e-271), while 1307 (~20%) overlap with both 
C/ebpα and Pu.1 (Figure 4.4).  
Figure 4.4 Overlap of Hoxa9, C/ebpα and Pu.1 binding peaks 
 
Figure 4.4. Overlap of Hoxa9, C/ebpα and Pu.1 binding peaks. (A) Venn Diagram showing the 




loci (Irf2, Dnajc10) co-bound by C/ebpα and Pu.1. Density plots were generated from raw read 
data and loaded into the UCSC Genome Browser as custom tracks. Blue indicates Hoxa9 
binding signal. Red indicates C/ebpα binding signal. Green indicates Pu.1 binding signal. Light 
blue indicates H3K4me1 binding signal. Purple indicates H3K27me3 binding signal and gray 
indicates input signal which serves as control.  
This is also supported by motif analysis. First, the Hoxa9 binding peaks were scanned 
for known transcription factor binding motifs against MatBase (Genomatix), which 
contains 865 motifs. 91% of Hoxa9 peaks contain HOXA9 motif (Z score=10.54, Z 
score >2 or <-2 corresponds to p-value <0.05) and 60% contain HOX-MEIS1 
combinatorial binding motif (Z score=13.39), confirming the quality of the ChIP-seq. 
Notably, 95% of Hoxa9 peaks contain ETS (PU.1) binding motif (Z score=26.49) and 
74% contain C/EBP binding motif (Z score=29.21) (Figure 4.5A). Further, de novo 
motif discovery using MEME-ChIP discovered that ETS and C/EBP motifs are 
enriched in Hoxa9 binding regions (E value= 1.1e-343, 2.6e-32, respectively. E value < 
0.001 is considered to be significant) (Machanick and Bailey, 2011) (Figure 4.5B). 
Two other motifs discovered by this approach are STAT and RUNX motifs (Figure 




Figure 4.5 Motif analysis of Hoxa9 binding peaks 
 
Figure 4.5 Motif analysis of Hoxa9 binding peaks. (A). Motif scanning of Hoxa9 binding peaks 
was performed by Genomatix against MatBase. Bar graph shows the percentages of Hoxa9 
binding peaks that contain the indicated motifs. For all the four motifs, Z score >10. (B). 
STAMP logo of the six motifs discovered by de novo motif analysis that have significant 
enrichment in Hoxa9 binding peaks. E values indicate the significance (comparable to 
p-values). 
4.4.3 Hoxa9, C/ebpα and Pu.1 cobound regions are enriched with enhancer 
marks  
As Hoxa9 binding regions are enriched with the enhancer mark H3K4me1, and Pu.1 
has been reported to promote H3K4me1 and enhancer establishment, we would like to 
determine if co-binding of C/ebpα and Pu.1 affects the level of histone marks. To test 
this, the Hoxa9 binding peaks were divided into four classes, those only bound by 
Hoxa9, co-bound by Hoxa9 and C/ebpα, co-bound by Hoxa9 and Pu.1 and co-bound by 
all three. The read densities of H3K4me1 and H3K27me3 3kb up- and downstream of 
the center of Hoxa9 peaks were normalized and calculated for each of the four classes 




H3K4me1. Notably, the triple-bound peaks have the highest level of enrichment; 
double-bound peaks of Hoxa9 and C/ebpα or Hoxa9 and Pu.1 show similar levels of 
enrichment, which is lower than the triple-bound peaks, while peaks only bound by 
Hoxa9 have the lowest level of enrichment (Figure 4.6A). Further, H3K27me3 mark 
was depleted from these peaks, with triple-bound regions having the highest level of  
depletion, and single-bound regions having the lowest level of depletion (Figure 4.6B). 
These data support that co-binding of C/ebpα and Pu.1 associates with enriched active 
enhancer marks.  
Figure 4.6 Distribution of histone marks around Hoxa9 binding peaks with 
different co-bindings of C/ebpα and Pu.1 
 
Figure 4.6. Distribution of histone marks around Hoxa9 binding peaks with different 
co-bindings of C/ebpα and Pu.1. (A). Distribution of Hoxa9 peaks co-bound by C/ebpα or Pu.1. 




Hoxa9 and C/ebpα. Blue indicates peaks co-bound by Hoxa9 and Pu.1. Red indicates peaks 
co-bound by Hoxa9, C/ebpα and Pu.1. (B-C). Density of H3K4me1 (B) and H3K27me3 (C) 
around Hoxa9 binding peaks with different co-binding patterns. The X-axis shows distance 
from the peaks. 0 indicates center of the peaks, and negative and positive values indicate 
upstream and downstream, respectively. Y-axis shows normalized average number of reads for 
each binding pattern. Colors corresponds to binding patterns the same way as in (A), with green 
indicating peaks that are only bound by Hoxa9, purple indicating peaks co-bound by Hoxa9 and 
C/ebpα, blue indicating peaks co-bound by Hoxa9 and Pu.1 and red indicating peaks co-bound 
by Hoxa9, C/ebpα and Pu.1. Grey indicates signals of the input. 
Further, to characterize the genes associated with the Hoxa9 peaks with or without 
co-binding of C/ebpα and Pu.1, pathway analysis on single- and triple-bound regions 
was performed using GREAT (McLean et al., 2010). Indeed, genes associated with 
triple-bound regions are highly enriched for hematopoiesis related pathways, such as 
immunity and immune cell physiology (p-value<0.001). Although the single-bound 
regions are also enriched with a few hematopoiesis related pathways, the significance 




Figure 4.7 Hoxa9, C/ebpα and Pu.1 co-bound regions associate with genes 
involved in hematopoiesis 
 
Figure 4.7. Hoxa9, C/ebpα and Pu.1 co-bound regions associate with genes involved in 
hematopoiesis. Pathway analysis of regions bound only by Hoxa9 (upper panel) and regions 
co-bound by Hoxa9, C/ebpα and Pu1 (lower panel). Analysis was performed using GREAT 
against the mouse phenotype database, y axis indicates top 10 enriched pathways, x axis 
indicates -10*log (p-value). 
4.4.4 C/ebpα and Pu.1 associate with Hoxa9-responsive genes 
The presence of C/ebpα and Pu.1 on Hoxa9 binding sites suggest that they are Hoxa9 
cofactors and cooperate with Hoxa9 to regulate gene expression. To test this, we would 
like to answer two questions: Does co-binding of C/ebpα and Pu.1 affect the 
responsiveness of the genes to Hoxa9? And does it specify the activation or repression 
activity of Hoxa9? To this end, we first sought to define the genome-wide target genes 
of Hoxa9. Withdrawal of 4-OHT blocks translocation of Hoxa9-ER into the nucleus, 




extracted from cells cultured in the presence of 4-OHT and at 72hrs upon withdrawal of 
4-OHT, which is approximately the earliest time point that depletion of Hoxa9 on 
representative binding sites (those used in Figure 4.1A) was observed by ChIP-qPCR 
experiments. RNA-sequencing was then performed with duplicated samples on 
Illumina™ HiSeq2000 system. More than 20 million reads were obtained for each 
sample and aligned to the reference genome. For differential expression analysis, two 
programs were tested and compared, the Tophat-Cuffdiff module (Kim et al., 2013; 
Trapnell et al., 2010) and EdgeR package (Robinson et al., 2010). The two methods 
generated similar results and Tophat-Cuffdiff was used for later analysis (Figure 4.8A). 
Upon 4-OHT withdrawal, 774 genes were up-regulated and 420 genes were 
down-regulated (FDR<0.05), consistent with previous report that Hoxa9 both activates 
and represses gene expression (Huang et al., 2012). Gene Set Enrichment Analysis 
(GSEA) was performed (Subramanian et al., 2005), showing that genes up-regulated 
with 4-OHT withdrawal are enriched with genes repressed in hematopoietic stem cells 
(False discovery rate (FDR)=0, Normalized enrichment score (NES)=1.99) and 
leukemia stem cells (FDR=0, NES=1.94), indicating that loss of Hoxa9 leads to loss of 
stem cell signature, supporting the role of Hoxa9 in maintaining hematopoietic stem 




Figure 4.8 Hoxa9 regulates stem cell signature genes 
 
Figure 4.8. Hoxa9 regulates stem cell signature genes. (A) Venn diagram showing the number 
of genes with significant expression change detected by CuffDiff (blue) and EdgeR (red). 
(B-C) Gene set enrichment analysis discovered that hematopoietic stem cell signature (B) and 
leukemic stem cell signature (C) were reversed upon 4-OHT withdrawal. FDR: false 
discovery rate. NES: normalized enrichment score. 
Genes with changed expression may be directly or indirectly regulated by Hoxa9, thus 
we define “Hoxa9 core target genes” as genes that are both bound by Hoxa9 and have 
expression change for more than 1.5 fold upon 4-OHT withdrawal. To this end, we 
mapped the 6578 Hoxa9 binding peaks to the nearest gene, and obtained 3602 unique 
genes (15.6% of the total number of genes detected in RNA-seq) that are nearest to one 
or more Hoxa9 peaks. Among these 3602 genes, 739 genes meet the criteria (Hoxa9 




These 739 genes represent 20.51% (out of 3602) of the Hoxa9-bound genes. The 
percentage is significantly higher than that of non-Hoxa9 bound genes, as only 6.72% 
(1292 out of 19214) of those showed significant change in expression (one sided 
Fisher exact test p-value<2.2e-16) (Figure 4.9A). To further test if the responsiveness 
of the genes to Hoxa9 activity is affected by co-binding of C/ebpα and Pu.1, genes 
bound by Hoxa9 were further divided into four classes: those only bound by Hoxa9 
(985 genes), co-bound by Hoxa9 and C/ebpα (1294 genes) or Pu.1 (364 genes) and 
co-bound by all three of them (1048 genes). Notably, 14.51% (143 out of 985) of the 
genes only bound by Hoxa9 showed significant change; the percentages are higher for 
double-bound genes by Hoxa9 and C/ebpα (20.94%, 271 out of 1294) or Pu.1 
(21.42%, 78 out of 364); while the triple-bound genes have the highest percentage, 
which is 25.85% (271 out of 1048, Appendix. B) (Chi square test of the five classes 
p-value < 2.2e-16, and the pairwise Fisher exact one-sided test p-values are shown in 
Figure 4.9C). These data support that C/ebpα and Pu.1 associate with genes that are 




Figure 4.9 Co-binding of C/ebpα and Pu.1 associates with Hoxa9 responsive genes 
 
 
Figure 4.9. Co-binding of C/ebpα and Pu.1 associates with Hoxa9 responsive genes. (A) Bar 
graph showing the percentage of genes with significant expression change upon 4-OHT 
withdrawal in none-Hoxa9 and Hoxa9 bound genes. Black indicates up-regulated genes upon 
4-OHT withdrawal. Grey indicates down-regulated genes upon 4-OHT withdrawal. (B) Bar 
graph showing the percentage of genes with significant expression change upon 4-OHT 
withdrawal in genes that are not bound by Hoxa9, bound only by Hoxa9, co-bound by Hoxa9 
and C/ebpα or Pu.1 and co-bound by Hoxa9, C/ebpα and Pu.1. Black indicates up-regulated 
genes upon 4-OHT withdrawal. Grey indicates down-regulated genes upon 4-OHT withdrawal. 
(C). Matrix showing pairwise p-values of Fisher Exact test comparing the percentages of 





However, binding of Hoxa9 does not associate with the magnitude of gene expression 
change, as for both up- and down-regulation upon 4-OHT withdrawal, the global fold 
change are comparable between non-Hoxa9 bound genes and Hoxa9 bound genes 
(Wilcoxon Rank Sum two-sided test p-value= 0.09817 for up-regulated genes, p-value 
= 0.06788 for down-regulated genes) (Figure 4.10A and B). Fold change was also 
compared among genes with different co-bindings of C/ebpα and Pu.1. No difference 
was detected for up-regulated genes (Kruskal-Wallis test p-value= 0.06152) (Figure 
4.10C). For down-regulated genes, only those with co-binding of Hoxa9 and Pu.1 
show slightly higher fold change compared to other groups (Kruskal-Wallis test 




Figure 4.10 Co-binding of C/ebpα and Pu1 does not associate with specific 
activity of Hoxa9 
 
Figure 4.10. Co-binding of C/ebpα and Pu1 does not associate with the magnitude of gene 
expression change. (A) Boxplot showing the log2 transformed fold change of genes with 
significant up-regulation upon 4-OHT withdrawal in none-Hoxa9 and Hoxa9 bound genes. (B) 
Boxplot showing the log2 transformed fold change of genes with significant up-regulation 
upon 4-OHT withdrawal with different binding patterns. (C) Boxplot showing the log2 
transformed fold change of genes with significant down-regulation upon 4-OHT withdrawal in 
none-Hoxa9 and Hoxa9 bound genes.  (D) Boxplot showing the log2 transformed fold 
change of genes with significant down-regulation upon 4-OHT withdrawal with different 
binding patterns. log2 transformed fold change for genes with co-binding of Hoxa9 and Pu.1 
is higher compared to those with no Hoxa9, Hoxa9 alone, Hoxa9 and C/ebpα and Hoxa9, 
C/ebpα and Pu.1, with pairwise Wilcoxon Rank Sum two-sided test p-values = 0.001513, 
0.01255, 0.01662, 0.02069, respectively). 
Finally, we tested if co-binding of C/ebpα and Pu.1 is associated with activation or 
repression activity of Hoxa9. For genes with significant expression change upon 




(activated by Hoxa9) （Figure 4.9A）. This percentage is comparable to those bound 
by Hoxa9, which is 45.06% (Fisher Exact test two-sided p-value = 0.05561). Further, 
no difference was detected when comparing genes with different co-bindings of 
C/ebpα and Pu.1 (Chi square test p-value= 0.1089) (Figure 4.9B). These data indicate 
that co-binding of C/ebpα and Pu.1 does not specify the activation or repression 
activity of Hoxa9. 
4.5  Discussion 
The development of high throughput sequencing technologies, such as ChIP-seq and 
RNA-seq, has greatly improved our ability to study protein-DNA interaction or gene 
transcription in the genome-wide scale, and revolutionized the way for biomedical 
research. Despite the advantage of these techniques as being fast, economic and 
highly reproducible, the generation of large amount of data brings challenge for the 
development of analysis algorithms. For ChIP-seq analysis, peak calling is the key 
step. Currently, there are more than thirty programs that use different ways to 
generate reads density, model peak distribution, adjust for background and assign 
peaks to genomic regions (Wilbanks and Facciotti, 2010), so they work differently in 
balancing sensitivity, which is the ability to “detect more peaks”, and specificity, 
which is the ability to “detect real peaks”, and may give very different results. So 
choosing the proper method for data analysis according to the need of study is critical. 




CisGenome and ChIPseeqer. MACS models the distribution of reads on the genome 
using poisson distribution with dynamic parameter λ estimated from nearby genomic 
regions. Also, it estimates the length of the sequencing fragments and shifts peaks 
accordingly, which increases the accuracy in estimating the center of peaks (Zhang et 
al., 2008). CisGenome is one of the earliest developed peak calling programs and 
gains its popularity by having a graphical user interface. Cisgenome uses conditional 
binomial model to estimate the distribution of reads (Ji et al., 2008). ChIPseeqer, as 
MACS, also uses a poisson model to estimate the reads distribution, but adjusts the 
length of fragment length by extending reads to the average length of the DNA 
fragment in the ChIP-seq library (Giannopoulou and Elemento, 2011). For Hoxa9 
ChIP-seq data, the results of the three programs show significant overlap, although the 
total numbers of peaks detected are quite different. MACS detected the largest 
number of peaks, while ChIPseeqer detected the smallest number of peaks (Figure 
4.1). Comparing to several gene loci that have been confirmed by ChIP-qPCR assays 
to have Hoxa9 binding, we found that although ChIPseeqer and CisGenome both 
detected the regions with high level of Hoxa9 binding, they missed some regions with 
median level of Hoxa9 binding, while MACS has higher sensitivity and detected all 
the regions with high and median levels Hoxa9 binding. Notably, the high sensitivity 
of MACS does not associate with an obvious loss of specificity, as although we 
cannot obtain the “true Hoxa9 binding sites”, more than 90% of MACS peaks are 




specific experiment, we conclude that MACS performs best in detecting Hoxa9 
binding.  
Similar to ChIP-seq, several methods have been developed for differential expression 
analysis of RNA-seq data. In this study, we tested and compared two methods, EdgeR 
package, which uses overdispersed poisson model to estimate the variation in the 
sequencing read counts (Robinson et al., 2010) and empirical Bayes method to 
estimate the degree of overdispersion, and Cuffdiff from Cufflinks RNA-Seq analysis 
tools, which uses beta negative binomial model to estimate variability across 
replicates and variability caused by ambiguously mapped reads from gene isoforms 
(Trapnell et al., 2010). Using the same alignment method (Tophat), the two methods 
give very similar results (Figure 4.8), indicating the consistency of these algorithms. 
Cuffdiff detects slightly fewer differentially expressed genes, possibly because taking 
into consideration of the isoform information decreases the false discovery rate.  
In this study, we characterized the genome-wide binding for Hoxa9, C/ebpα and Pu.1, 
and found that all these three transcription factors predominantly bind to intergenic 
and intronic regions, supporting their role in enhancer function. Hoxa9, C/ebpα and 
Pu.1 have significant overlap on the genome, and the co-bound regions are enriched 
with the enhancer marker H3K4me1 (Figure 4.4). Specifically, triple-bound regions 
by Hoxa9, C/ebpα and Pu.1 have the highest levels of H3K4me1, double-bound 




lowest level of enrichment (Figure 4.6), supporting the role of C/ebpα and Pu.1 in 
promoting H3K4me1 and enhancer establishment. Notably, the depletion of 
H3K27me3, the poised enhancer marker, indicates that these enhancers play active 
roles in transcription regulation (Figure 4.6). Consistent with this, co-binding of 
C/ebpα and Pu.1 associates with genes whose expression are responsive to Hoxa9 
activity. These data support that C/ebpα and Pu.1 are Hoxa9 cofactors and cooperate 
with Hoxa9 to regulate gene expression. Indeed, our lab observed that depletion of 
C/ebpα or Pu.1 in Hoxa9-Meis1 transformed cells blocks transformation, reflected by 
cell differentiation and decreased cell proliferation (unpublished data). Important 
questions remain to be answered. Especially, how does Hoxa9 cooperate with C/ebpα 
and Pu.1? Does binding of one factor affect the recruitment of the other two? Also, 
although Hoxa9, C/ebpα and Pu.1 co-bound regions associate with higher percentage 
of genes response to Hoxa9 activity (25%), the majority of these genes do not respond, 
and C/ebpα and Pu.1 co-binding does not specify the activation or repression activity 
of Hoxa9 (Figure 4.9). Are there other co-factors, either on the enhancers or 
promoters, also involved in this transcriptional regulation? These questions will be the 




Chapter5 Concluding Remarks and Future Directions 
The MLL-HOXA9 axis plays a critical role in the regulation of development and 
hematopoiesis. Chromosome translocations of MLL are closely associated with 
human leukemia and constitutive activation of HOXA9 is required for the 
leukemogenesis. Although being studied for decades, important questions remain to 
be answered in this field. For example, how is the activity of MLL regulated during 
hematopoiesis? What are the mechanisms of MLL fusion-mediated transformation? 
And how does HOXA9 regulate gene expression and mediate leukemogenesis? The 
work described in this dissertation touches every aspect of the above questions.  
In Chapter 2 and Chapter 3, I addressed the first two questions by studying the 
function of the PHD/Bromo region of MLL. This region is invariably disrupted or 
deleted in oncogenic MLL fusion proteins and is incompatible to MLL fusion 
mediated transformation. We found that this region mediates MLL ubiquitination in 
multiple ways. The bromodomain recruits ECS
ASB2
 E3 ligase complex through 
interaction with ASB2. ECS
ASB2
 mediates ubiquitination and degradation of MLL 
during hematopoietic differentiation, thus contributing to the down-regulation of MLL 
target genes, including HOXA9 and MEIS1. This is important for the normal 
progression of hematopoiesis, as knockdown of ASB2 stabilizes MLL and blocks cell 




MLL has intrinsic E3 ligase activity in the presence of the E2 conjugating enzyme 
CDC34. This activity requires the intact structure of the PHD finger and is conserved 
in the second PHD finger of MLL4. Further, mutation of PHD2 affects MLL stability 
and transactivation ability. These data support a model in which the activity and 
stability of MLL is regulated by ubiquitination in multiple ways, possibly depending 
on different biological context (Figure 5.1). Notably, the oncogenic MLL fusion 
proteins do not have the PHD/Bromo region, and are resistant to both degradation 
pathways. The increased protein stability may contribute to MLL fusion mediated 
transformation.  
Figure 5.1 Model for the function of the PHD/Bromodomain in MLL 
ubiquitination 
 
Figure 5.1 Model for the function of the PHD/Bromodomain in MLL ubiquitination. The 
bromodomain interacts with ASB2 and recruits the ECS
ASB2
 E3 ligase complex, while the 
second PHD finger interacts with CDC34 and has intrinsic E3 ligase activity. It remains to be 
determined if there is any crosstalk between ECS
ASB2
 mediated MLL ubiquitination and PHD2 




An interesting and important question that arises from examining the PHD/Bromo 
region of MLL is what are the biological functions of ASB2. The rapid expression of 
ASB2 upon cell differentiation and its effect on MLL degradation supports its role as 
a positive regulator of hematopoietic differentiation. It will be interesting to establish 
a knockout mouse model of Asb2 and systematically assess its functions in embryonic 
development and hematopoiesis, specifically, whether depletion of Asb2 leads to 
hyperproliferation of hematopoietic cells, and sensitizes these cells to leukemogenic 
transformation. Also, besides MLL, FilaminA and FilaminB, ASB2 may have other 
substrates that remain to be discovered. Among the MLL family proteins, MLL4 
shares the greatest sequence similarity to MLL, raising the possibility that ASB2 can 
also ubiquitinate MLL4. Indeed, blast of MLL bromodomain and flanking sequences 
(aa1631-1934) reveals a region in MLL4 (1401-1642) that shares 40% sequence 
identity. Experiments are needed to determine if ASB2 is a specific E3 ligase of MLL, 
or it also regulates MLL4 and other MLL family proteins. Further, ASB2 contains 
twelve ankyrin repeats which are implicated to mediate the interaction with its 
substrates. We mapped the interaction between ASB2 and MLL to the first five 
ankyrin repeats, which may not be the minimal region required for this interaction. 
Co-localization of ASB2 and FilaminA requires the first ten ankyrin repeats but the 
direct interaction may be mediated only by the N-terminal twenty amino acid residues 
that are structurally homologous to filamin-binding motifs (Lamsoul et al., 2011). So 




Identifying these substrates, for example, by mass spectrometry, and studying their 
functions in hematopoiesis and other biological processes will provide insights for the 
functions of ASB2.  
A recent study reports that the wild-type allele of MLL is required for MLL-AF9 
mediated leukemogenesis, as knockdown or excision of wild-type Mll in MLL-AF9 
transduced cells inhibits cell proliferation, reduces colony formation and inhibits the 
development of leukemia in vivo (Thiel et al., 2010). Based on these observations, the 
authors propose that MLL fusion protein-transformed leukemia cells may be more 
sensitive to inhibition of wild-type MLL, as they have a reduced cellular level of MLL, 
and wild-type MLL is a potential target for leukemia therapy (Thiel et al., 2010). This is 
consistent with our findings, as ASB2 expression in MLL-AF9 transformed cells 
phenocopies knockdown or excision of wild-type MLL, including decreased H3K4 
methylation, decreased HoxA9 expression and reduced cell proliferation and colony 
formation. Notably, ASB2 expression is rapidly induced by ATRA (Guibal et al., 2002; 
Kohroki et al., 2001). This suggests that ATRA treatment, which is already in use for 
treatment of promyelocytic leukemia, would have activity against MLL associated 
leukemias. Indeed, two leukemia cell lines harboring the MLL-AF9 fusion protein, 
THP-1 and MOLM-14 cells, have been shown to be sensitive to ATRA induced 
differentiation (Matsushita et al., 2008). More MLL associated leukemia cell lines need 




Other than ASB2, several members of the ASB family have potential roles in 
hematopoiesis as well. The expression profile of these Asb genes during 
differentiation of Hoxa9-ER/Meis1 transformed cells reveals that besides Asb2, which 
has increased expression upon cell differentiation, three other Asb genes, Asb8, Asb11 
and Asb13 show decreased expression in this process, indicating that they may have 
opposite functions in hematopoiesis to Asb2 (Figure 2.13A). Notably, ASB11 has 
been shown in zebrafish to be required for proper neurogenesis by activating the 
Notch signaling pathway, which is also a critical signaling pathway for self-renewal 
in hematopoietic stem cells (Diks et al., 2008; Sartori da Silva et al., 2010). The 
function of ASB8 and ASB13 is still unknown. It will be interesting to study the 
function of these ASB proteins in hematopoiesis, which may reveal novel regulators 
of this process.  
The biological significance of the MLL PHD2 E3 ligase activity also remains to be 
determined. Considering the role of CDC34 as a master regulator of cell cycle (King 
et al., 1996), it is possible that PHD2 regulates MLL degradation during cell cycle 
progression. It will be interesting to establish a cell line with MLL PHD2 mutants, for 
example, in Mll
-/-
 MEF cells, and test its effect on cell cycle progression and Mll 
target gene expression.  
Further, it will be interesting to test if PHD2 has other substrates besides 




ubiquitinates histone H3 and H4, but not H2A and H2B. The ubiquitination sites were 
further identified to be H3K79, H3K122 and H4K31. All these sites have been shown 
to be ubiquitinated in vivo using proteomics approaches, while their functions remain 
unknown (Kim et al., 2011; Wagner et al., 2011). Further, sequence analysis reveals 
that the flanking sequences of these sites share similarity, which may be preferentially 
recognized and ubiquitinated by PHD2 (Basu et al., 2009). It remains to be 
determined if histone H3 and H4 are bona fide substrates of MLL PHD2 in vivo, and 
if so, what are the biological functions. These three sites on histone H3 and H4 can be 
modified by other post-translational modifications. Especially, H3K79 is methylated 
by DOT1L, which is a cofactor of MLL fusion proteins and is required for MLL 
fusion mediated transformation (Okada et al., 2005). H3K122 can be acetylated, 
which promotes transcription (Tropberger et al., 2013). Ubiquitination may compete 
with these modifications and represents a second way that MLL regulates 
transcription besides H3K4 methylation. Further, it has been shown that MLL 
mediated histone H3K4 methylation depends on ubiquitination of histone H2B (Kim 
et al., 2009). It will be interesting to test if PHD2 mediated ubiquitination affects 
H3K4 methylation, which may represent another layer of histone crosstalk.  
Besides ubiquitin, proteins are conjugated with other ubiquitin-like molecules, which 
regulate protein stability and activity (Herrmann et al., 2007). The PHD finger of 




et al., 2007). This activity is critical for the recruitment of NuRD, as both SETDB1 
and CHD3, the subunits of NuRD complex, contain a SUMO-interacting motif and 
interact with KAP1 through sumo binding (Capili et al., 2001; Ivanov et al., 2007; 
Zeng et al., 2008). In MLL, PHD2 and the bromodomain are also adjacent to each 
other. It is worth testing if PHD2 has sumo ligase activity, for example, to interact 
with the SUMO E2 conjugating enzyme UBC9, and mediate sumoylation of the 
bromodomain or other substrates. Further, as the bromodomain mediates interaction 
with ASB2, this modification may affect the interaction between MLL and ASB2, and 
ASB2 mediated MLL ubiquitination. Besides SUMO protein, NEDD8 is another 
ubiquitin-like protein. NEDD8 has been shown to be conjugated to all Cullin proteins. 
This neddylation results in conformational rearrangements of the ECS complex, 
which are necessary for ubiquitin transfer to a substrate (Soucy et al., 2010). It 
remains to be determined if PHD2 can mediate conjugation of NEDD8 on Cullin5 and 
regulates its activity, which may represent another way of crosstalk between PHD2 
and ECS
ASB2
 mediated MLL ubiquitination.  
Finally, although the structure for the binding of PHD fingers to histone modifications 
is well studied, the structure and sequence basis of the PHD fingers with E3 ligase 
activity remains unknown. It will be important to characterize the interaction between 
these PHD fingers and the E2 conjugating enzymes, and determine the key foldings 




PHD fingers, and also provide insights for development of PHD finger inhibitors for 
therapeutic applications.  
In Chapter 4, I explored the mechanisms of HOXA9 regulated gene expression by 
studying the cooperation between Hoxa9 and its potential cofactors C/ebpα and Pu.1 
using high throughput sequencing technologies. Analysis of ChIP-seq and RNA-seq 
data reveals that genome-wide binding of C/ebpα and Pu.1 significantly overlaps with 
the binding of Hoxa9. Further, the co-bound regions have enriched enhancer marker 
H3K4me1 and are associated with hematopoiesis related pathways and 
Hoxa9-responsive genes.  
Experiments are ongoing to study the biological significance of C/ebpα and Pu.1 for 
the function of Hoxa9 in normal and malignant hematopoiesis. Indeed, our 
preliminary data show that depletion of C/ebpα or Pu.1 in Hoxa9/Meis1 transformed 
cells blocks transformation, reflected by cell differentiation and decreased cell 
proliferation (unpublished data), supporting that these two proteins are required for 
Hoxa9/Meis1 mediated transformation. Along with this, it is important to map the 
interaction regions on Hoxa9, C/ebpα and Pu.1, as disruption of these interactions 
may have therapeutic values for Hoxa9 mediated leukemia. The mechanisms of the 
recruitment of the three proteins remained to be determined. It has been reported that 
C/ebpα and Pu.1 establish the enhancer elements and prime recruitment of the NF-κB 




the same mechanism works for Hoxa9. The lab has obtained conditional knockout 
mice for C/ebpα and Pu.1, which enables us to deplete one or both of these proteins 
and monitor the recruitment of Hoxa9, and the establishment of the enhancer marks.  
Further, the ChIP-seq and RNA-seq data provide a valuable resource to study other 
aspects of Hoxa9 regulated gene expression. For example, does the location of Hoxa9 
binding on different genomic regions (promoter/intergenic/intronic regions) or with 
different distances from the transcription start sites correlate with gene expression? 
Also, combining the ChIP-seq and RNA-seq data, we obtained the genes that are 
bound by Hoxa9 (and its cofactors) and have their expression regulated by Hoxa9. It 
will be important to find the key genes and pathways for Hoxa9 regulated 
hematopoiesis and leukemogenesis. Finally, co-binding of C/ebpα and Pu.1 does not 
predict the activation or repression activity of Hoxa9, so the direction of Hoxa9’s 
activity still remains a mystery. Other possibilities can be explored. For example, 
separate motif analysis of Hoxa9 binding regions associated with activated or 
repressed genes may reveal additional Hoxa9 cofactors involved in this process. Or 
the histone mark on gene promoters may determine the direction of gene transcription 
together with the enhancer mark. Deciphering the functional interaction between 
Hoxa9 and its cofactors will provide not only insight for Hoxa9 regulated gene 
expression, but also potential therapeutic targets for Hoxa9 associated leukemia and 




Appendix A. Core Hoxa9 Target Genes 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix B. Core Hoxa9 Target Genes with Co-binding of C/ebpα and Pu.1 
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